AN INFECTIOUS cDNA CLONE OF NORTH AMERICAN PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS AND USES THEREOF

ABSTRACT

The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of U.S. patent application Ser. No. 11/366,851, filed on Mar. 1, 2006, which is a continuation-in-part of U.S. patent application Ser. No. 10/241,332, filed Sep. 11, 2002, which is a continuation-in-part of U.S. patent application Ser. No. 10/127,391, filed on Apr. 22, 2002, which is a continuation of U.S. patent application Ser. No. 09/470,661, filed Dec. 22, 1999, U.S. Pat. No. 6,500,662, which claims the benefit of priority of U.S. Provisional Application Ser. No. 60/113,345, filed Dec. 22, 1998, the disclosures of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The present invention is in the field of animal health and is directed to infectious cDNA clones of positive polarity RNA viruses and the construction of vaccines, in particular, swine vaccines, using such cDNA clones.

BACKGROUND OF THE INVENTION

Porcine reproductive and respiratory syndrome (PRRS) is a new disease of swine, first described in 1987 in North America and in 1990 in Europe. The disease has since spread to Asia and affects most of the major swine producing countries of the world. Primary symptoms are reproductive problems in sows and gifts, including late term abortions, stillbirths and mummies, and litters of small weak pigs which are born viremic and often fail to survive. In addition, the syndrome manifests itself as a respiratory disease in young pigs which spreads horizontally and causes fever, lethargy, labored breathing, loss of appetite, slow growth, and occasionally death, often in association with other respiratory pathogens. The disease furthermore can be transmitted to sows and gilts via the semen of infected boars, either naturally or by artificial insemination. For these, and other reasons, PRRS has proven to be a difficult disease to control and therefore one of the most economically damaging diseases to the swine industry.

The causative agent of PRRS is the PRRS virus, which exists as two genetically and serologically distinct types (Murtaugh, M. P. et al, 1995, Arch-Virol. 140, 1451-1460; Suarez, P. et al., 1996, Virus Research 42:159-165). The two types are believed to have first entered swine populations independently, one in North America and the other in Europe, in the 1980's, from unknown biological reservoirs, possibly of rodent or avian origin. The European type, represented by the prototype “Lelystad Virus”, was isolated and sequenced in the Netherlands in 1991 (Terpstra, C. et al., 1991, Vet. Quart. 13:131-136; Wensvoort, G. et al., 1991, Vet. Quart. 13:121-130; Wensvoort, G. et al., WO 92/213751992 (PCT/NL92/00096), 1992; Meulenberg, J. J. M. et al., 1993, Virol. 192:62-72).

Both the North American PRRS virus and the European PRRS virus are classified within the family Arteriviridae, which also includes equine arteritis virus, lactate dehydrogenase-elevating virus, and simian haemorrhagic fever virus. The arteriviruses are in turn placed within the order Nidovirales, which also includes the coronaviruses and toroviruses. The nidoviruses are enveloped viruses having genomes consisting of a single strand of positive polarity RNA. The genomic RNA of a positive-stranded RNA virus fulfills the dual role in both storage and expression of genetic information. No DNA is involved in replication or transcription in nidoviruses. The reproduction of nidoviral genomic RNA is thus a combined process of genome replication and mRNA transcription. Moreover, some proteins are translated directly from the genomic RNA of nidoviruses. The molecular biology of the family Arteriviridae has recently been reviewed by Snijder and Meulenberg (Snijder, E. J. and Meulenberg, J. J. M., 1998, Journal of General Virology 79:961-979).

Currently available commercial vaccines against PRRS are either conventional modified live virus (cell culture, attenuated) or conventional killed (inactivated cell culture preparations of virulent virus). Several of these vaccines have been criticized based on safety and/or efficacy concerns. The development of a second generation of PRRS vaccines, based upon specific additions, deletions, and other modifications to the PRRS genome, is therefore highly desirable. However, since the PRRS viruses do not include any DNA intermediates during their replication, such vaccines have thus far awaited the construction of full-length cDNA clones of PRRS viruses for manipulation by molecular biology techniques at the DNA level. Very recently, a full-length infectious cDNA clone of the European PRRS virus has been reported (Meulenberg, J. J. M. et al., 1998, supra; Meulenberg, J. J. M. et al, 1988, J. Virol. 72, 380-387.).

The preceding publications, as well as all other references discussed below in this application, are hereby incorporated by reference in their entireties.

SUMMARY OF THE INVENTION

The subject invention provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that when it infects a porcine animal it is unable to produce PRRS in the animal yet able to elicit an effective immunoprotective response against a PRRS virus in the porcine animal, wherein said DNA sequence is SEQ ID NO:1 or a sequence homologous thereto, except that it lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus.

The subject invention further provides an isolated polynucleotide molecule where at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus in ORF 1a or ORF 1b within said DNA sequence is deleted.

The subject invention further provides an isolated polynucleotide molecule where at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus in the nonstructural protein 2 coding region of ORF1a within said DNA sequence is deleted.

The subject invention further provides an isolated polynucleotide molecule where at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence is deleted.

The subject invention further provides an isolated polynucleotide molecule where the DNA sequence encoding amino acids 628 and 759 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence is deleted.

The subject invention further provides a vaccine for protecting a porcine animal from infection by a PRRS virus, wherein said vaccine comprises a genetically modified North American PRRS virus encoded by an infectious RNA molecule encoded by the isolated polynucleotide molecule as described above; an infectious RNA molecule encoded by the isolated polynucleotide molecule as described above; an isolated polynucleotide molecule as described above in the form of a plasmid, or a viral vector comprising the isolated polynucleotide molecule as described above, and a carrier acceptable for veterinary use.

The subject invention also provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that when it infects a porcine animal it is unable to produce PRRS in the animal yet able to elicit an effective immunoprotective response against a PRRS virus in the porcine animal, wherein the DNA sequence is SEQ ID NO:1 or a sequence homologous thereto, except that it lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus, wherein it further comprises at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope.

The present invention further provides an isolated polynucleotide molecule comprising at least one nucleotide sequence encoding a heterologous antigenic epitope, wherein said nucleotide sequence encoding a heterologous antigenic epitope is inserted in ORF 1a or ORF 1b within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

The present invention further provides an isolated polynucleotide molecule comprising at least one nucleotide sequence encoding a heterologous antigenic epitope, wherein said nucleotide sequence encoding a heterologous antigenic epitope is inserted in the nonstructural protein 2 coding region of ORF 1a within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

The present invention further provides an isolated polynucleotide molecule comprising at least one nucleotide sequence encoding a heterologous antigenic epitope, wherein said nucleotide sequence encoding a heterologous antigenic epitope is inserted in the hypervariable region in the nonstructural protein 2 coding region of ORF 1a within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

The present invention further provides an isolated polynucleotide molecule comprising at least one nucleotide sequence encoding a heterologous antigenic epitope, wherein said nucleotide sequence encoding a heterologous antigenic epitope is inserted in the hypervariable region in the nonstructural protein 2 coding region of ORF 1a between the DNA sequence encoding amino acids 628 and 759 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.

The present invention further provides a vaccine for protecting a porcine animal from infection by a PRRS virus, wherein said vaccine comprises a genetically modified North American PRRS virus encoded by an infectious RNA molecule encoded by an isolated polynucleotide molecule as described above, an infectious RNA molecule encoded by an isolated polynucleotide molecule as described above, an isolated polynucleotide molecule as described above, or a viral vector comprising an isolated polynucleotide molecule as described above, and a carrier acceptable for veterinary use.

The present invention also provides a diagnostic kit for differentiating between porcine animals vaccinated with the above described vaccines and porcine animals infected with field strains of PRRS virus. Said kit contains as one of its components at least one peptide having a sequence comprising the 132 amino acid region deleted within the PRRS virus strains presently described. Alternative, the kit can have as one of its components the corresponding peptide from any PRRS virus strain. The kit can otherwise have as one of its components a smaller peptide corresponding to a portion of the 132 amino acid sequence comprising the nsp2 deletion, from 10 amino acid residues or upward in length. The peptide can additionally be in the form of a fusion protein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: Cloning strategy for construction of full-length infectious cDNA clone of North American PRRS virus, pT7P129A. Arrowheads represent T7 promoter sequences.

FIG. 2: Serum viremia following infection with P129A or recombinant PRRS virus rP129A-1. Determined by plaque assay on MARC-145 cells. The lower limit of detection is 5 pfu/ml (or 0.7 on the log scale).

FIG. 3: Anti-PRRS virus serum antibody following infection with P129A or recombinant PRRS virus rP129A-1. Determined by HerdChek PRRS ELISA assay (IDEXX (Westbrook, Me., USA)).

FIG. 4: Genome organization of PRRSV virus. Location or range of various deletions and insertion sites, including: ORF 1a and 1b, Nsp2, the hypervariable region of Nsp2, the deleted region within Nsp2 encoding amino acids 628-759, and the MluI and SgrA1 sites at genome positions 3219 and 3614, between which GFP or the 9 amino acid HA tag were inserted. The active site residues of the cysteine protease domain (Cys437 and His507) and the hypervariable region are indicated. The hypervariable region of nsp2 corresponds approximately to genome coordinates 2720-3980 in P129.

DETAILED DESCRIPTION OF THE INVENTION

Production and manipulation of the isolated polynucleotide molecules described herein are within the skill in the art and can be carried out according to recombinant techniques described, among other places, in Maniatis, et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Ausubel, et al., 1989, Current Protocols In Molecular Biology, Greene Publishing Associates & Wiley Interscience, NY; Sambrook, at al., 1989, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Innis at alt (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1992, PCR Technology, Oxford University Press, New York, all of which are incorporated herein by reference.

A. Isolated Polynucleotide Molecules and RNA Molecules Encoding Genetically Modified North American PRRS Viruses.

The present invention provides isolated polynucleotide molecules comprising DNA sequences that encode infectious RNA molecules that encode genetically modified North American PRRS viruses.

The subject invention provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule that encodes a North American PRRS virus, wherein said DNA sequence is SEQ ID NO:1 or a sequence homologous thereto. The present invention provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule that encodes a North American PRRS virus, wherein said DNA sequence is the sequence beginning with and including nucleotide 1 through and including nucleotide 15,416 of SEQ ID NO:1, except that the nucleotide corresponding to nucleotide 12,622 of SEQ ID NO:1 is a guanine instead of an adenine and the nucleotide corresponding to nucleotide 1,559 of SEQ ID NO:1 is a thymine instead of a cytosine. Said DNA sequence encodes an infectious RNA molecule that is the RNA genome of the North American PRRS isolate P129.

It is understood that terms herein referring to nucleic acid molecules such as “isolated polynucleotide molecule”, “nucleotide sequence”, “open reading frame (ORF)”, and the like, unless otherwise specified, include both DNA and RNA molecules and include both single-stranded and double-stranded molecules. Also, when reference to a particular sequence from the “Sequence Listing” section of the subject application is made, it is intended, unless otherwise specified, to refer to both the DNA of the “Sequence Listing”, as well as RNA corresponding to the DNA sequence, and includes sequences complementary to the DNA and RNA sequences. In such contexts in this application, “corresponding to” refers to sequences of DNA and RNA that are identical to one another but for the fact that the RNA sequence contains uracil in place of thymine and the backbone of the RNA molecule contains ribose instead of deoxyribose.

For example, SEQ ID NO:1 is a DNA sequence corresponding to the RNA genome of a North American PRRS virus. Thus, a DNA sequence complementary to the DNA sequence set forth in SEQ ID NO:1 is a template for, i.e. is complementary to or “encodes”, the RNA genome of the North American PRRS virus (i.e., RNA that encodes the North American PRRS virus). Nonetheless, a reference herein to SEQ ID NO:1 includes both the RNA sequence corresponding to SEQ ID NO:1 and a DNA sequence complementary to SEQ ID NO:1.

Furthermore, when reference is made herein to sequences homologous to a sequence in the Sequence Listing, it is to be understood that sequences homologous to a sequence corresponding to the sequence in the Sequence Listing and sequences homologous to a sequence complementary to the sequence in the Sequence Listing are also included.

An “infectious RNA molecule”, for purposes of the present invention, is an RNA molecule that encodes the necessary elements for viral replication, transcription, and translation into a functional virion in a suitable host cell, provided, if necessary, with a peptide or peptides that compensate for any genetic modifications, e.g. sequence deletions, in the RNA molecule.

An “isolated infectious RNA molecule” refers to a composition of matter comprising the aforementioned infectious RNA molecule purified to any detectable degree from its naturally occurring state, if such RNA molecule does indeed occur in nature. Likewise, an “isolated polynucleotide molecule” refers to a composition of matter comprising a polynucleotide molecule of the present invention purified to any detectable degree from its naturally occurring state, if any.

For purposes of the present invention, the nucleotide sequence of a second polynucleotide molecule (either RNA or DNA) is “homologous” to the nucleotide sequence of a first polynucleotide molecule where the nucleotide sequence of the second polynucleotide molecule encodes the same polyaminoacid as the nucleotide sequence of the first polynucleotide molecule as based on the degeneracy of the genetic code, or when it encodes a polyaminoacid that is sufficiently similar to the polyaminoacid encoded by the nucleotide sequence of the first polynucleotide molecule so as to be useful in practicing the present invention. For purposes of the present invention, a polynucleotide molecule is useful in practicing the present invention where it can be used as a diagnostic probe to detect the presence of the North American PRRS virus in a fluid or tissue sample of an infected pig, e.g. by standard hybridization or amplification techniques. It is to be understood that the polyaminoacid encoded by the nucleotide sequence of the polynucleotide molecule can comprise a group of two or more polyaminoacids. Generally, the nucleotide sequence of a second polynucleotide molecule is homologous to the nucleotide sequence of a first polynucleotide molecule if it has at least about 70% nucleotide sequence identity to the nucleotide sequence of the first polynucleotide molecule as based on the BLASTN algorithm (National Center for Biotechnology Information, otherwise known as NCBI, (Bethesda, Md., USA) of the United States National Institute of Health). Preferably, a homologous nucleotide sequence has at least about 75% nucleotide sequence identity, even more preferably at least about 85% nucleotide sequence identity. Since the genetic code is degenerate, a homologous nucleotide sequence can include any number of “silent” base changes, i.e. nucleotide substitutions that nonetheless encode the same amino acid. A homologous nucleotide sequence can further contain non-silent mutations, i.e. base substitutions, deletions, or additions resulting in amino acid differences in the encoded polyaminoacid, so long as the sequence remains at least about 70% identical to the polyaminoacid encoded by the first nucleotide sequence or otherwise is useful for practicing the present invention. Homologous nucleotide sequences can be determined by comparison of nucleotide sequences, for example by using BLASTN, above. Alternatively, homologous nucleotide sequences can be determined by hybridization under selected conditions. For example, the nucleotide sequence of a second polynucleotide molecule is homologous to SEQ ID NO:1 if it hybridizes to the complement of SEQ ID NO:1 under moderately stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.2×SSC/0.1% SDS at 42° C. (see Ausubel et al. above), or conditions which will otherwise result in hybridization of sequences that encode a North American PRRS virus as defined below. In another embodiment, a second nucleotide sequence is homologous to SEQ ID NO:1 if it hybridizes to the complement of SEQ ID NO:1 under highly stringent conditions, e.g. hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C. (Ausubel et al., above).

It is furthermore to be understood that the isolated polynucleotide molecules and the isolated RNA molecules of the present invention include both synthetic molecules and molecules obtained through recombinant techniques, such as by in vitro cloning and transcription.

As used herein, the term “PRRS” encompasses disease symptoms in swine caused by a PRRS virus infection. Examples of such symptoms include, but are not limited to, abortion in pregnant females, and slow growth, respiratory difficulties, loss of appetite, and mortality in young pigs. As used herein, a PRRS virus that is “unable to produce PRRS” refers to a virus that can infect a pig, but which does not produce any disease symptoms normally associated with a PRRS infection in the pig, or produces such symptoms, but to a lesser degree, or produces a fewer number of such symptoms, or both.

The terms “porcine” and “swine” are used interchangeably herein and refer to any animal that is a member of the family Suidae such as, for example, a pig. “Mammals” include any warm-blooded vertebrates of the Mammalia class, including humans.

The term “PRRS virus”, as used herein, unless otherwise indicated, means any strain of either the North American or European PRRS viruses.

The term “field strain” or “field strains”, as used herein, unless otherwise indicated, means any strain of either North American or European PRRS virus which occurs in nature, and is infectious to a pig.

The term “North American PRRS virus” means any PRRS virus having genetic characteristics associated with a North American PRRS virus isolate, such as, but not limited to the PRRS virus that was first isolated in the United States around the early 1990's (see, e.g., Collins, J. E., et al., 1992, J. Vet. Diagn. Invest, 4:117-126); North American PRRS virus isolate MN-1b (Kwang, J. et al., 1994, J. Vet. Diagn. Invest. 6:293-296); the Quebec IAF-exp91 strain of PRRS (Mardassi, H. et al., 1995, Arch. Virol. 140:1405-1418); and North American PRRS virus isolate VA 2385 (Meng, X.-J et al., 1994, J. Gen. Virol 75:1795-1801). Genetic characteristics refers to genomic nucleotide sequence similarity and amino acid sequence similarity shared by North American PRRS virus strains. For purposes of the present invention, a North American PRRS virus is a virus that is encoded by an RNA sequence the same as or homologous to SEQ ID NO:1, wherein the term “homologous” is as defined previously. Thus, strains of North American PRRS viruses have, preferably, at least about 70% genomic nucleotide sequence identity with SEQ ID NO:1, and more preferably at least about 75% genomic nucleotide sequence identity with SEQ ID NO:1, at least about 85% genomic nucleotide sequence identity with SEQ ID NO:1 being even more preferred.

The term “European PRRS virus” refers to any strain of PRRS virus having the genetic characteristics associated with the PRRS virus that was first isolated in Europe around 1991 (see, e.g., Wensvoort, G., et al., 1991, Vet. Q. 13:121-130). “European PRRS virus” is also sometimes referred to in the art as “Lelystad virus”.

Unless otherwise indicated, a North American PRRS virus is “useful in practicing the present invention” if its characteristics are within the definition of a North American PRRS virus set forth herein. For example, a virus encoded by one of the isolated polynucleotide molecules of the present invention is a “North American PRRS virus useful in practicing the present invention” if it, e.g., has genetic characteristics associated with a North American PRRS virus.

Other polyaminoacids are “useful in practicing the present invention”, e.g., peptides encoded by polynucleotide sequences homologous to North American PRRS virus ORFs, if they can compensate for an RNA molecule encoding a genetically modified PRRS virus, deficient in a gene essential for expressing functional PRRS virions, in a transfected host cell so that functional PRRS virions can be generated by the cell.

The term “open reading frame”, or “ORF”, as used herein, means the minimal nucleotide sequence required to encode a particular PRRS virus protein without an intervening stop codon.

Terms such as “suitable host cell” and “appropriate host cell”, unless otherwise indicated, refer to cells into which RNA molecules (or isolated polynucleotide molecules or viral vectors comprising DNA sequences encoding such RNA molecules) of the present invention can be transformed or transfected. “Suitable host cells” for transfection with such RNA molecules, isolated polynucleotide molecules, or viral vectors, include mammalian, particularly porcine, and avian cells, and are described in further detail below.

A “functional virion” is a virus particle that is able to enter a cell capable of hosting a PRRS virus, and express genes of its particular RNA genome (either an unmodified genome or a genetically modified genome as described herein) within the cell. Cells capable of hosting a PRRS virus include porcine alveolar macrophage cells and MARC 145 monkey kidney cells. Other mammalian or avian cells, especially other porcine cells, may also serve as suitable host cells for PRRS virions.

The isolated polynucleotide molecules of the present invention encode North American PRRS viruses that can be used to prepare live, killed, or attenuated vaccines using art-recognized methods for protecting swine from infection by a PRRS virus, as described in further detail below. These isolated polynucleotide molecules are also useful as vectors for delivering heterologous genes into mammals, including swine, or birds, as is also described in detail below. Furthermore, these isolated polynucleotide molecules are useful because they can be mutated using molecular biology techniques to encode genetically-modified North American PRRS viruses useful, inter alia, as vaccines for protecting swine from PRRS infection. Such genetically-modified North American PRRS viruses, as well as vaccines comprising them, are also described in further detail below.

The term “genetically modified”, as used herein and unless otherwise indicated, means genetically mutated, i.e. having one or more nucleotides replaced, deleted and/or added. Polynucleotide molecules can be genetically mutated using recombinant techniques known to those of ordinary skill in the art, including by site-directed mutagenesis, or by random mutagenesis such as by exposure to chemical mutagens or to radiation, as known in the art. In one embodiment, genetic modification of the North American PRRS virus of the present invention renders the virus unable to replicate effectively, or reduces its ability to replicate effectively, in a bird or mammal in which the wild-type virus otherwise can effectively replicate. In another embodiment, the genetically modified North American PRRS virus of the present invention remains able to replicate effectively in birds or mammals infected therewith. “Effective replication” means the ability to multiply and produce progeny viruses (virions) in an infected animal, i.e. the ability to “productively infect” an animal.

The subject invention further provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule which encodes a genetically modified North American PRRS virus that is unable to produce PRRS in a porcine animal, wherein the DNA sequence encoding the infectious RNA molecule encoding said North American PRRS virus is SEQ ID NO:1 or a sequence homologous thereto, except that it contains one or more mutations that genetically disable the encoded PRRS virus in its ability to produce PRRS. “Genetically disabled” means that the PRRS virus is unable to produce PRRS in a swine animal infected therewith.

The subject invention also provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule which encodes a North American PRRS virus that is genetically modified such that when it infects a porcine animal it: a) is unable to produce PRRS in the animal, and b) is able to elicit an effective immunoprotective response against infection by a PRRS virus in the animal, wherein the DNA sequence encoding said North American PRRS virus is SEQ ID NO:1 or a sequence homologous thereto, except that it contains one or more mutations that genetically disable the encoded PRRS virus in its ability to produce PRRS.

The term “immune response” for purposes of this invention means the production of antibodies and/or cells (such as T lymphocytes) that are directed against, or assist in the decomposition or inhibition of, a particular antigenic epitope or particular antigenic epitopes. The phrases “an effective immunoprotective response”, “immunoprotection”, and like terms, for purposes of the present invention, mean an immune response that is directed against one or more antigenic epitopes of a pathogen so as to protect against infection by the pathogen in a vaccinated animal. For purposes of the present invention, protection against infection by a pathogen includes not only the absolute prevention of infection, but also any detectable reduction in the degree or rate of infection by a pathogen, or any detectable reduction in the severity of the disease or any symptom or condition resulting from infection by the pathogen in the vaccinated animal as compared to an unvaccinated infected animal. An effective immunoprotective response can be induced in animals that have not previously been infected with the pathogen and/or are not infected with the pathogen at the time of vaccination. An effective immunoprotective response can also be induced in an animal already infected with the pathogen at the time of vaccination.

An “antigenic epitope” is, unless otherwise indicated, a molecule that is able to elicit an immune response in a particular animal or species. Antigenic epitopes are proteinaceous molecules, i.e. polyaminoacid sequences, optionally comprising non-protein groups such as carbohydrate moieties and/or lipid moieties.

The term “pathogenically infecting” used herein refers to the ability of a pathogen to infect an animal and cause a disease in the animal. As an example, a PRRS virus is capable of pathogenically infecting a porcine animal since it can cause PRRS in swine. However, although a PRRS virus may be able to infect, either productively or non-productively, a bird or another mammal, such as a human, it does not pathogenically infect any animal other than a porcine animal since it does not cause any disease in animals other than porcine animals.

The genetically modified North American PRRS viruses encoded by the above-described isolated polynucleotide molecules are, in one embodiment, able to elicit an effective immunoprotective response against infection by a PRRS virus. Such genetically modified North American PRRS viruses are preferably able to elicit an effective immunoprotective response against any strain of PRRS viruses, including both European and North American strains.

The present invention provides a mutation or mutations in the isolated polynucleotide molecule encoding the genetically disabled North American PRRS virus that are non-silent and occur in one or more open reading frames of the nucleotide sequence encoding the North American PRRS virus; i.e., the mutation or mutations occur in one or more of the sequences within the nucleotide sequence encoding the North American PRRS virus that are the same as or homologous to ORFs 1a, 1b, 2, 3, 4, 5, 6, or 7 of SEQ ID NO:1. The mutation or mutations may occur in one or more noncoding regions of the North American PRRS virus genome, such as, for example, in the leader sequence of the North American PRRS virus genome; i.e., the mutation or mutations occur within the sequence that is the same as or homologous to the sequence of nucleotides 1-191 of SEQ ID NO:1. In the same isolated polynucleotide molecule, mutations can occur in both coding and noncoding regions.

As used herein, unless otherwise indicated, “noncoding regions” of the nucleotide sequence encoding the North American PRRS virus refer to those sequences of RNA that are not translated into a protein and those sequences of cDNA that encode such RNA sequences. Coding regions refer to those sequences of RNA from which North American PRRS virus proteins are expressed, and also refer to cDNA that encodes such RNA sequences. Likewise, “ORFs” refer both to RNA sequences that encode North American PRRS virus proteins and to cDNA sequence encoding such RNA sequences.

Determining suitable locations for a mutation or mutations that will encode a North American PRRS virus that is genetically disabled so that it is unable to produce PRRS yet remains able to elicit an effective immunoprotective response against infection by a PRRS virus can be made based on the SEQ ID NO:1 provided herein. One of ordinary skill can refer to the sequence of the infectious cDNA clone of North American PRRS virus provided by this invention, make sequence changes which will result in a mutation, and test the viruses encoded thereby both for their ability to produce PRRS in swine, and to elicit an effective immunoprotective response against infection by a PRRS virus. In so doing, one of ordinary skill can refer to techniques known in the art and also those described and/or exemplified herein.

For example, an ORF of the sequence encoding the infectious RNA molecule encoding the North American PRRS virus can be mutated and the resulting genetically modified North American PRRS virus tested for its ability to cause PRRS. The ORF of a North American PRRS virus encodes proteins as follows: ORF 1a encodes a polyprotein comprising protease function; ORF 1b encodes a polyprotein comprising replicase (RNA polymerase) and helicase functions; ORFs 2, 3, and 4 encode small membrane glycoproteins; ORF 5 encodes a major envelope glycoprotein; ORF 6 encodes a nonglycosylated integral membrane protein; and ORF 7 encodes a nucleocapsid protein. Genetic mutations of one or more of these ORFs can be used in preparing the genetically modified North American PRRS viruses described infra.

The subject invention also provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that it lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus, wherein the DNA sequence encoding the RNA molecule encoding the North American PRRS virus is SEQ ID NO:1 or a sequence homologous thereto.

A “detectable antigenic epitope” is, unless otherwise indicated, a molecule that is able to elicit an immune response in a particular animal or species, which immune response is measurable via an assay or method.

In a non-limiting embodiment, the detectable antigenic epitope which is deleted is within ORF 1a or OAF 1b. In another embodiment, the detectable antigenic epitope which is deleted is within the sequences encoding for the nonstructural protein 2 (nsp2), which is part of ORF 1a. In a separate embodiment, the detectable antigenic epitope which is deleted is within the hypervariable C-terminal portion of nsp2. In a further embodiment, the detectable antigenic epitope which is deleted, or lacking, is the DNA sequence encoding any 10 aa polypeptides or longer, up to 400 aa length polypeptides, where the DNA sequence that may be deleted is the DNA that encodes any amino acids from 616 to 752 of the hypervariable region of nsp2. This region, from 616 to 752 of nsp2, is the conserved sub-region within the hypervariable region of nsp2.

One example of such a deletion is Example XI. In Example XI a deletion is described which results in the lack of a DNA sequence encoding amino acids 628 through 759 of nsp2. This deletion is within the region encoding the hypervariable C-terminal portion of nsp2. This Example XI deletion, which lacks the DNA sequence encoding amino acids from 628 to 759 in the hypervariable region is considered as being taken from the region of the DNA sequence encoding amino acids 616 to 752 in the hypervariable region because the region begins in the region of the DNA sequence encoding amino acids 616 to 752 in the hypervariable region. The deleted region can extend beyond the conserved sub-region in either direction, but the entire deleted region should be no greater than the amount of DNA that encodes for a polypeptide of about 400 aa. Table 1 shows the relative positions of some of the nucleotides and amino acids in relation to certain regions of the genome for SEQ. ID. NO. 1.

TABLE 1 Genome coordinates of nsp2 regions based on SEQ ID NO. 1. Genome Amino Amino position acid range acid range Landmark (nucleotides) (w/in ORF1a) (w/in nsp2) Entire 1-15,450 NA NA genome (1-15,395 w/o polyA tail) ORF1a 192-7685    1-2497 NA (7491 nt) (2497 aa) ATGTCT...TGCTAG MSGIL...QCLNC Nsp2 1341-4262  384-1357   1-974 (2922 nt) (974 aa) (974 aa) GCTGGA...CTGGGC AGKRA...GRLLG AGKRA...GRLLG Hypervariable 2721-3980  844-1263 461-880 region of nsp2 (1260 nt) (420 aa) (420 aa) AGATCT...CTCTTT RSDYG...LFCLF RSDYG...LFCLF Conserved 3186-3596  999-1135 616-752 subregion w/in (411 nt) (137 aa) (137 aa) hypervariable region TCATCA...CGCATC SSSSS...DIPRI SSSSS...DIPRI Deletion in 3222-3617 1011-1142 628-759 Example XI (396 nt) (132 aa) (132 aa) CGCCCA...AATACC RPKYS...KIENT RPKYS...KIENT

Such deletions may be anywhere within the hypervariable region, including the region of the DNA encoding the conserved sub-region of amino acids from 616 to 752 in nsp2, and such deletions may extend into the flanking regions as well, provided the DNA encodes at least 10 amino acids from the conserved sub-region or from other locations in the hypervariable region.

In a further embodiment, the detectable antigenic epitope which is removed is taken from the DNA sequence encoding amino acids 628 through 759 of nsp2, which is both within the conserved sub-region and within the region encoding the hypervariable C-terminal portion of nsp2.

In a further embodiment, the detectable antigenic epitope which is deleted is taken from the DNA sequence encoding polypeptides as short as ten amino acids, or as long as the entire hypervariable region of nsp2 which can extend up to 400 amino acids. Specifically the region may be from 10 to 100 aa in length, from 100 to 150, from 150 to 200, from 200 to 300 or from 300 to 400 amino acids in length. For example, the deleted DNA can encode the peptide that comprises amino acids 1-10 of the hypervariable region of the nsp2 peptide. The peptide can be amino acids 2-11 of the hypervariable region. The peptide can be amino acids 3-12 of the hypervariable region. Peptides are selected in this fashion by progressively “walking” down the amino acid sequence of the hypervariable region of nsp2, all of the way through the hypervariable region, more particularly through the region of the DNA encoding the conserved subregion of amino acids from 616 to 752 of nsp2 within the hypervariable region, and it may extend into the flanking regions. A specific example of this is Example XI where the deleted region is the DNA sequence encoding amino acids 628 through 759 in the hypervariable region.

In addition to 10-mer peptides, the deleted fragment can be a DNA encoding 11 amino acid residues in length, beginning with a fragment comprising amino acid 1-11 of the hypervariable region, and progressing to the C-terminal end of the hypervariable region. Similarly, the fragment can be DNA encoding 12, 13, 14, 15, 16, 17, 18, 19, 20 or more residues in length, up to 400 residues in length, and such peptides are readily identifiable by beginning at residue 1 and “walking” down the amino acid sequence of the corresponding hypervariable region of nsp2. Such a strategy can be applied to the corresponding hypervariable region of the nsp2 sequence from any strain of PRRS virus.

The subject invention also provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that it lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus, wherein it further comprises one or more heterologous antigenic epitopes, wherein the DNA sequence encoding the RNA molecule encoding the North American PRRS virus is SEQ ID NO:1 or a sequence homologous thereto, and further comprising one or more additional nucleotide sequences that each encode a heterologous antigenic epitope, and wherein each heterologous antigenic epitope is capable of inducing an effective immunoprotective response against a particular pathogen in a mammal or a bird.

A pathogen against which an effective immunoprotective response can be induced by means of the above recited aspect of the present invention is any pathogen, such as a virus, bacteria, fungus, or protozoan, capable of causing a disease in a mammal or bird, which pathogen comprises or has associated therewith one or more antigenic epitopes which can be used to induce an effective immunoprotective response against the pathogen in the mammal or bird.

The term “heterologous antigenic epitope” for purposes of the present invention means an antigenic epitope, as defined above, not normally found in a wild-type North American PRRS virus. A nucleotide sequence encoding a heterologous antigenic epitope can be inserted into a North American PRRS viral genome using known recombinant techniques. Antigenic epitopes useful as heterologous antigenic epitopes for the present invention include additional North American PRRS virus antigenic epitopes, antigenic epitopes from European PRRS viruses, antigenic epitopes from swine pathogens other than PRRS viruses, or antigenic epitopes from pathogens that pathogenically infect birds or mammals other than swine, including humans. Sequences encoding such antigenic epitopes are known in the art or are provided herein. For example, a second North American PRRS virus envelope protein, encoded by North American PRRS ORF 5 described herein, can be inserted into a DNA sequence encoding an RNA molecule encoding a North American PRRS virus of the present invention to generate a genetically modified North American PRRS virus comprising an additional envelope protein as a heterologous antigenic epitope. Such a genetically modified North American PRRS virus can be used to induce a more effective immunoprotective response against PRRS viruses in a porcine animal vaccinated therewith.

Examples of an antigenic epitope from a swine pathogen other than a North American PRRS virus include, but are not limited to, an antigenic epitope from a swine pathogen selected from the group consisting of European PRRS, porcine parvovirus, porcine circovirus, a porcine rotavirus, swine influenza, pseudorabies virus, transmissible gastroenteritis virus, porcine respiratory coronavirus, classical swine fever virus, African swine fever virus, encephalomyocarditis virus, porcine paramyxovirus, Actinobacillus pleuropneumoni, Bacillus anthraci, Bordetela bronchiseptica, Clostridium haemolyticum, Clostridium perfringens, Clostridium tetani, Escherichia coli, Erysipelothrix rhusiopathiae, Haemophilus parasuis, Leptospira spp., Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Pasteurella haemolytica, Pasteurella multocida, Salmonella choleraesuis, Salmonella typhimudum, Streptococcus equismilis, and Streptococcus suis. Nucleotide sequences encoding antigenic epitopes from the aforementioned swine pathogens are known in the art and can be obtained from public gene databases such as GenBank (http/www.ncbi.nlm.nih.gov/Web/Genbank/index.html) provided by NCBI.

If the heterologous antigenic epitopes are antigenic epitopes from one or more other swine pathogens, then the isolated polynucleotide molecule can further contain one or more mutations that genetically disable the encoded PRRS virus in its ability to produce PRRS. Such isolated polynucleotide molecules and the viruses they encode are useful for preparing vaccines for protecting swine against the swine pathogen or pathogens from which the heterologous antigenic epitopes are derived.

The present invention provides a genetically modified North American PRRS virus able to elicit an effective immunoprotective response against infection by a PRRS virus in a porcine animal. Such isolated polynucleotide molecules and the viruses they encode are useful for preparing dual-function vaccines for protecting swine against infection by both a North American PRRS virus and the swine pathogen or pathogens from which the heterologous antigenic epitopes are derived.

The isolated polynucleotide molecules of the present invention comprising nucleotide sequences encoding heterologous antigenic epitopes can be prepared as described above based on the sequence encoding a North American PRRS virus described herein using known techniques in molecular biology.

In one embodiment, the additional nucleotide sequences that each encode a heterologous antigenic epitope are inserted into the DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus within an open reading frame encoding for a PRRS virus protein. In a non-limiting embodiment, the additional nucleotide sequences are inserted in ORF 1a or ORF 1b. In another embodiment, the additional nucleotide sequences are inserted within sequences encoding for the nonstructural protein 2 (nsp2), which is part of ORF 1a. In a separate embodiment, the additional nucleotide sequences are inserted within the region encoding the hypervariable C-terminal portion of nsp2. In a further embodiment, the additional nucleotide sequences are inserted between the DNA sequence encoding amino acids 628 and 759 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence, which is within the region encoding the hypervariable C-terminal portion of nsp2. See FIG. 4.

The hypervariable region of nsp2 corresponds approximately to genome coordinates 2720-3980 in P129. See FIG. 4.

In a separate embodiment, the additional nucleotide sequences that each encode a heterologous antigenic epitope are inserted into the DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus within the sequences encoding any of ORFs 1a, 1b, 2, 3, 4, 5, 6, or 7. See FIG. 4.

In another embodiment, a heterologous antigenic epitope of the genetically modified North American PRRS virus of the present invention is a detectable antigenic epitope. Such isolated polynucleotide molecules and the North American PRRS viruses they encode are useful, interalia, for studying PRRS infections in swine, determining successfully vaccinated swine, and/or for distinguishing vaccinated swine from swine infected by a wild-type PRRS virus. Preferably, such isolated polynucleotide molecules further contain one or more mutations that genetically disable the encoded PRRS virus in its ability to produce PRRS, and more preferably are able to elicit an effective immunoprotective response in a porcine animal against infection by a PRRS virus.

Heterologous antigenic epitopes that are detectable, and the sequences that encode them, are known in the art. Techniques for detecting such antigenic epitopes are also known in the art and include serological detection of antibody specific to the heterologous antigenic epitope by means of, for example, Western blot, ELISA, or fluorescently labeled antibodies capable of binding to the antibodies specific to the heterologous antigenic epitope. Techniques for serological detection useful in practicing the present invention can be found in texts recognized in the art, such as Coligan, J. E., et al (eds), 1998, Current Protocols in Immunology, John Willey & Sons, Inc., which is hereby incorporated by reference in its entirety. Alternatively, the heterologous antigenic epitope itself can be detected by, for example, contacting samples that potentially comprise the antigenic epitope with fluorescently-labeled antibodies or radioactively-labeled antibodies that specifically bind to the antigenic epitopes.

The present invention further provides an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule which encodes a genetically modified North American PRRS virus that detectably lacks a North American PRRS virus antigenic epitope, wherein the DNA sequence encoding the RNA molecule encoding the North American PRRS virus is SEQ ID NO:1 or a sequence homologous thereto, except that it lacks one or more nucleotide sequences encoding a detectable North American PRRS virus antigenic epitope. Such isolated polynucleotide molecules are useful for distinguishing between swine infected with a recombinant North American PRRS virus of the present invention and swine infected with a wild-type PRRS virus. For example, animals vaccinated with killed, live or attenuated North American PRRS virus encoded by such an isolated polynucleotide molecule can be distinguished from animals infected with wild-type PRRS based on the absence of antibodies specific to the missing antigenic epitope, or based on the absence of the antigenic epitope itself: If antibodies specific to the missing antigenic epitope, or if the antigenic epitope itself, are detected in the animal, then the animal was exposed to and infected by a wild-type PRRS virus. Means for detecting antigenic epitopes and antibodies specific thereto are known in the art, as discussed above. Preferably, such an isolated polynucleotide molecule further contains one or more mutations that genetically disable the encoded PRRS virus in its ability to produce PRRS. More preferably, the encoded virus remains able to elicit an effective immunoprotective response against infection by a PRRS virus.

B. Vaccines and Uses Thereof.

The present invention also provides vaccines comprising North American PRRS viruses, including genetically modified North American PRRS viruses disabled in their ability to produce PRRS in a swine animal as described herein; infectious RNA molecules and plasmids encoding such North American PRRS viruses as described herein; and viral vectors encoding such North American PRRS viruses and isolated RNA molecules as described herein.

In one embodiment, the subject invention provides a vaccine comprising a genetically modified North American PRRS virus which lacks at least one detectable antigenic epitope as described herein, an infectious RNA molecule encoding such a genetically modified North American PRRS virus, a plasmid as described herein encoding such a genetically modified North American PRRS virus, or a viral vector encoding such a genetically modified North American PRRS virus, and a carrier acceptable for pharmaceutical or veterinary use, in an amount effective to elicit an immunoprotective response against PRRS virus infection in the porcine animal.

In another embodiment, the subject invention provides a vaccine comprising a genetically modified North American PRRS virus comprising one or more detectable heterologous antigenic epitopes as described herein, an infectious RNA molecule encoding such a genetically modified North American PRRS virus, a plasmid as described herein encoding such a genetically modified North American PRRS virus, or a viral vector encoding such a genetically modified North American PRRS virus, and a carrier acceptable for pharmaceutical or veterinary use.

Such vaccines can be used to protect from infection a mammal or a bird capable of being pathogenically infected by the pathogen or pathogens from which the detectable heterologous antigenic epitope(s) are derived. If such a vaccine comprises the genetically modified North American PRRS virus, the genetic modification of the North American PRRS virus preferably renders the virus unable to cause PRRS in swine. Thus, such would provide a dual-vaccine for swine, protecting swine from infection by the swine pathogen or pathogens from which the heterologous antigenic epitope(s) are derived as well as from infection by a PRRS virus. If the vaccine comprises an infectious RNA molecule or a plasmid encoding a genetically-modified North American PRRS virus comprising one or more heterologous antigenic epitopes from another swine pathogen, then the sequence encoding the infectious RNA molecule encoding the genetically modified PRRS virus preferably comprises one or more further mutations that genetically disable the encoded North American PRRS virus so that it is unable to cause PRRS. In another preferred embodiment, the encoded genetically modified, disabled North American PRRS virus is able to elicit an immunoprotective response against a PRRS infection in a swine animal, thus providing a dual-vaccine for swine, able to protect swine from infection by the swine pathogen or pathogens from which the heterologous antigenic epitope(s) are derived as well as from infection by a PRRS virus. All of these vaccines also further comprise a carrier acceptable for veterinary use.

Vaccines of the present invention can be formulated following accepted convention to include acceptable carriers for animals, including humans (if applicable), such as standard buffers, stabilizers, diluents, preservatives, and/or solubilizers, and can also be formulated to facilitate sustained release. Diluents include water, saline, dextrose, ethanol, glycerol, and the like. Additives for isotonicity include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin, among others. Other suitable vaccine vehicles and additives, including those that are particularly useful in formulating modified live vaccines, are known or will be apparent to those skilled in the art, See, e.g., Remington's Pharmaceutical Science, 18th ed., 1990, Mack Publishing, which is incorporated herein by reference.

Vaccines of the present invention may further comprise one or more additional immunomodulatory components such as, e.g., an adjuvant or cytokine, among others. Non-limiting examples of adjuvants that can be used in the vaccine of the present invention include the RIBI adjuvant system (Ribi Inc., Hamilton, Mont.), alum, mineral gels such as aluminum hydroxide gel, oil-in-water emulsions, water-in-oil emulsions such as, e.g., Freund's complete and incomplete adjuvants, Block copolymer (CytRx, Atlanta Ga.), QS-21 (Cambridge Biotech Inc., Cambridge Mass.), SAF-M (Chiron, Emeryville Calif.), AMPHIGEN® adjuvant, saponin, Quil A or other saponin fraction, monophosphoryl lipid A, and Avridine lipid-amine adjuvant. Non-limiting examples of oil-in-water emulsions useful in the vaccine of the invention include modified SEAM62 and SEAM 1/2 formulations. Modified SEAM62 is an oil-in-water emulsion containing 5% (v/v) squalene (Sigma), 1% (v/v) SPAN® 85 detergent (ICI Surfactants), 0.7% (v/v) TWEEN® 80 detergent (ICI Surfactants), 2.5% (v/v) ethanol, 200 μg/ml Quil A, 100 μg/ml cholesterol, and 0.5% (v/v) lecithin. Modified SEAM 1/2 is an oil-in-water emulsion comprising 5% (v/v) squalene, 1% (v/v) SPAN® 85 detergent, 0.7% (v/v) Tween 80 detergent, 2.5% (v/v) ethanol, 100 μg/ml Quil A, and 50 μg/ml cholesterol. Other immunomodulatory agents that can be included in the vaccine include, e.g., one or more interleukins, interferons, or other known cytokines.

Vaccines of the present invention can optionally be formulated for sustained release of the virus, infectious RNA molecule, plasmid, or viral vector of the present invention. Examples of such sustained release formulations include virus, infectious RNA molecule, plasmid, or viral vector in combination with composites of biocompatible polymers, such as, e.g., poly(lactic acid), poly(lactic-co-glycolic acid), methylcellulose, hyaluronic acid, collagen and the like. The structure, selection and use of degradable polymers in drug delivery vehicles have been reviewed in several publications, including A. Domb et al., 1992, Polymers for Advanced Technologies 3: 279-292, which is incorporated herein by reference. Additional guidance in selecting and using polymers in pharmaceutical formulations can be found in texts known in the art, for example M. Chasin and R. Langer (ads), 1990, “Biodegradable Polymers as Drug Delivery Systems” in: Drugs and the Pharmaceutical Sciences, Vol. 45, M. Dekker, NY, which is also incorporated herein by reference. Alternatively, or additionally, the virus, plasmid, or viral vector can be microencapsulated to improve administration and efficacy. Methods for microencapsulating antigens are well-known in the art, and include techniques described, e.g., in U.S. Pat. No. 3,137,631; U.S. Pat. No. 3,959,457: U.S. Pat. No. 4,205,060; U.S. Pat. No. 4,606,940; U.S. Pat. No. 4,744,933; U.S. Pat. No. 5,132,17; and International Patent Publication WO 95/28227, all of which are incorporated herein by reference.

Liposomes can also be used to provide for the sustained release of virus, plasmid, or viral vector. Details concerning how to make and use liposomal formulations can be found in, among other places, U.S. Pat. No. 4,016,100; U.S. Pat. No. 4,452,747; U.S. Pat. No. 4,921,706; U.S. Pat. No. 4,927,637; U.S. Pat. No. 4,944,948; U.S. Pat. No. 5,008,050; and U.S. Pat. No. 5,009,956, all of which are incorporated herein by reference.

An effective amount of any of the above-described vaccines can be determined by conventional means, starting with a low dose of virus, plasmid or viral vector, and then increasing the dosage while monitoring the effects. An effective amount may be obtained after a single administration of a vaccine or after multiple administrations of a vaccine. Known factors can be taken into consideration when determining an optimal dose per animal. These include the species, size, age and general condition of the animal, the presence of other drugs in the animal, and the like. The actual dosage is preferably chosen after consideration of the results from other animal studies.

One method of detecting whether an adequate immune response has been achieved is to determine seroconversion and antibody titer in the animal after vaccination. The timing of vaccination and the number of boosters, if any, will preferably be determined by a doctor or veterinarian based on analysis of all relevant factors, some of which are described above.

The effective dose amount of virus, infectious RNA molecule, plasmid, or viral vector, of the present invention can be determined using known techniques, taking into account factors that can be determined by one of ordinary skill in the art such as the weight of the animal to be vaccinated. The dose amount of virus of the present invention in a vaccine of the present invention preferably ranges from about 10¹ to about 10⁹ pfu (plaque forming units), more preferably from about 10² to about 10 pfu, and most preferably from about 10³ to about 10⁷ pfu. The dose amount of a plasmid of the present invention in a vaccine of the present invention preferably ranges from about 0.1 μg to about 100 mg, more preferably from about 1 μg to about 10 mg, even more preferably from about 10 μg to about 1 mg. The dose amount of an infectious RNA molecule of the present invention in a vaccine of the present invention preferably ranges from about 0.1 μg to about 100 mg, more preferably from about 1 μg to about 10 mg, even more preferably from about 10 μg to about 1 mg. The dose amount of a viral vector of the present invention in a vaccine of the present invention preferably ranges from about 10¹ pfu to about 10⁹ pfu, more preferably from about 10² pfu to about 10 pfu, and even more preferably from about 10³ to about 10⁷ pfu. A suitable dosage size ranges from about 0.5 ml to about 10 ml, and more preferably from about 1 ml to about 5 ml.

It is to be understood that the term “North American PRRS viruses of the present invention” and like terms, unless otherwise indicated, include any of the genetically modified North American PRRS viruses described herein as well as the unmodified North American PRRS virus described herein encoded by SEQ ID NO:1 or a sequence homologous thereto.

C. Diagnostic Kits

The present invention also provides diagnostic kits. The kit can be valuable for differentiating between porcine animals naturally infected with a field strain of a PRRS virus and porcine animals vaccinated with any of the vaccines described herein. The kits can also be of value because animals potentially infected with field strains of PRRS virus can be detected prior to the existence in the absence of clinical symptoms and removed from the herd, or kept in isolation away from naïve or vaccinated animals. The kits include reagents for analyzing a sample from a porcine animal for the presence of antibodies to a PRRS virus. Diagnostic kits of the present invention can include as a component a peptide or peptides which comprise all or a portion of a protein sequence which is no longer present in a genetically modified North American PRRS virus which may optionally comprise one or more detectable heterologous antigenic epitopes. Kits of the present invention can alternatively include as a component a peptide which is a fusion protein. The term “fusion peptide” or “fusion protein” for purposes of the present invention means a single polypeptide chain consisting of at least a portion of a PRRS virus protein and a heterologous peptide or protein.

D. Plasmids Encoding a North American PRRS Virus or a Genetically Modified North American PRRS Virus.

The present invention also provides any of the above-described isolated polynucleotide molecules in the form of a plasmid capable of expressing the North American PRRS virus encoded thereby.

Plasmids of the present invention can express the encoded North American PRRS virus outside of a living organism, to produce North American PRRS viruses of the invention useful, inter alia, for preparing vaccines. In one embodiment, a plasmid of the present invention capable of expressing a North American PRRS virus outside of a living organism is a plasmid wherein transcription of viral RNA therefrom occurs in vitro (i.e. extracellularly); the resulting viral RNA molecule is transfected into a suitable host cell using known mechanisms of transfection, such as electroporation, lipofection (in some cases using a commercially available reagent, such as Lipofectin™ (Life Technologies Inc., Rockville, Md., USA)), or DEAE dextran mediated transfection. Other methods of transfection are known in the art and can be employed in the present invention. An example of such a plasmid for in vitro transcription of North American PRRS viral RNA is the plasmid pT7P129A (ATCC Accession No. 203488). Any promoter useful for in vitro transcription can be used in such plasmids of this invention. T7 is one such promoter, but other promoters can be used, such as an SP6 promoter or a T3 promoter. The sequences of such promoters can be artificially synthesized or cloned from commercially available plasmids. Suitable plasmids for preparing such plasmids capable of expressing North American PRRS virus include, but are not limited to, general purpose cloning vector plasmids such as pCR2.1 (Invitrogen, Carlsbad, Calif., USA), pBR322, and pUC18. A nucleotide sequence of the present invention encoding the North American PRRS virus can be inserted into any of these plasmids using known recombinant techniques. Other plasmids into which the polynucleotide molecules of the present invention can be inserted will be recognized by those of ordinary skill in the art.

Suitable conditions for in vitro transcription of viral RNA from any of the above-described recombinant plasmids comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus depends on the type of plasmid, for example, its particular promoter, and can be ascertained by one of ordinary skill in the art. For example, if a plasmid of the present invention is based on a pCR2.1 plasmid comprising a T7 promoter, then an example of suitable conditions for in vitro transcription includes reacting the plasmid with T7 RNA polymerase and ribonucleotides in a standard buffer and incubating the reaction at 37° C. for about 30 minutes. In some cases, commercial kits are available for transcribing RNA from a particular plasmid, and such kits can be used in the present invention. The reaction mixture following transcription can be directly transfected into a suitable host cell without purification, or the transcribed North American PRRS virus RNA can be purified by known RNA purification techniques, for example by organic (e.g. phenol) extraction and alcohol (e.g. ethanol or isopropanol) precipitation, prior to transfection.

Transcription of the DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus, and further comprising one or more additional nucleotide sequences that each encode a heterologous antigenic epitope, results in the formation of a genomic and subgenomic RNA molecules. In one embodiment, at least one heterologous antigenic epitope is translated directly from the genomic RNA molecule. In another embodiment, at least one heterologous antigenic epitope is translated from a subgenomic RNA molecule that is synthesized from the genomic RNA.

The term “translation” for purposes of the present invention means the synthesis of protein from nucleotides such as an RNA molecule. In one embodiment, translation of the genomic or a subgenomic RNA molecule encoding a heterologous antigenic epitope results in synthesis of a peptide or protein consisting of the heterologous antigenic epitope itself. In another embodiment, translation of the genomic or a subgenomic RNA molecule results in synthesis of a fusion peptide or protein. The term “fusion peptide or protein” for purposes of the present invention means a single polypeptide chain consisting of at least a portion of a PRRS virus protein and at least one heterologous antigenic epitope.

Practically any mammalian or avian cell culture can be transfected with the North American PRRS virus RNA obtained as described above in order to generate a first round of North American PRRS virions. An example of cells which one might find particularly useful because of their ready availability and ease of use are BHK (baby hamster kidney) cells. However, if one wishes to generate a cell culture capable of sustained production of North American PRRS virions, then porcine alveolar macrophage cells or MARC-145 cells (Kim, H. S., et al., supra) are preferred since these cells excrete high levels of new generation PRRS virions subsequent to PRRS virus infection. Other cell lines derived from the MA-104 cell line may also be used for sustained generation of North American PRRS virions of the present invention. Primary porcine alveolar macrophage cells can be obtained by lung lavages from pigs, and the MARC-145 monkey kidney cell line can be obtained from the National Veterinary Services Laboratories otherwise known as NVSL (Ames, Iowa, USA).

In another embodiment, a plasmid capable of expressing a North American PRRS virus of the present invention outside of a living organism is a plasmid which is transfected into a suitable host cell, for example by electroporation or lipofection, transcription of the infectious RNA molecule and expression of the North American PRRS virus therefrom occurring within the transfected host cell. The transfected host cell therefore generates North American PRRS virions. Such a completely cellular method has heretofore never been disclosed or suggested for any virus within the order of Nidovirales. Because of possible cryptic splicing and termination sequences present in the RNA genome of viruses of the Nidovirales order, a completely cellular method of expressing a Nidovirales virus was believed unlikely. Cryptic sequences include RNA splice donor and splice acceptor sequences, which could cause inappropriate splicing of the RNA transcript, as well as polyadenylation sequences, which could cause premature termination by the cellular RNA polymerase II. The present invention demonstrates, however, that the presence of such sequences in a plasmid comprising a cDNA clone of a Nidovirus does not prevent the plasmid's ability to express the Nidovirus when the plasmid is directly transfected into a suitable host cell.

Accordingly, the subject invention also provides plasmids and a completely cellular method for expressing a Nidovirales virus, wherein the plasmid comprises: a) a DNA sequence encoding an infectious RNA molecule encoding the Nidovirales virus; and b) a promoter capable of transcribing said encoding sequence in a cell, wherein said promoter is in operative association with the DNA sequence encoding the infectious RNA molecule. The method comprises transfecting a suitable host cell with such a plasmid, subjecting the transfected host cell to conditions suitable for expression of gene sequences transfected therein, and collecting the expressed Nidovirales virus therefrom. An example of a plasmid suitable for completely cellular expression of North American PRRS virus outside of a living organism is the plasmid pCMV-S-P129 (ATCC Accession No. 203489). In a preferred embodiment, the promoter of such a plasmid is a CMV promoter. In a preferred embodiment, a plasmid of the invention suitable for a completely cellular method of expressing a Nidovirales virus comprises a eukaryotic promoter, such as a CMV promoter, immediately upstream and adjacent to the nucleotide sequence encoding the Nidovirales virus. In a preferred embodiment, the nucleotide sequence encoding the Nidovirales virus encodes a PRRS virus, either European or North American. Other examples of Nidovirales viruses that can be expressed by means of the above-described completely cellular method include other Arteriviruses such as, equine arteritis virus, lactate dehydrogenase-elevating virus, and simian haemorrhagic fever virus; viruses that are members of the genus Coronaviridae, such as, but not limited to, feline infectious peritinitis virus, feline enteric coronavirus, canine coronavirus, bovine coronavirus, porcine respiratory coronavirus, turkey coronavirus, porcine transmissible gastroenteritis virus, human coronavirus, murine hepatitis virus, and avian infectious bronchitis virus; and members of the genus Toroviridae, such as, but not limited to, Berne virus, Breda virus, and human torovirus. Thus, plasmids suitable for completely cellular expression comprising a nucleotide sequence encoding one of these viruses are also encompassed by the present invention.

Suitable plasmids that can be used to prepare recombinant plasmids of the present invention for completely cellular expression outside of a living organism of a Nidovirales virus, such as a PRRS virus, include virtually any plasmid useful for transfection and expression in eukaryotic cells. An examples of a plasmid suitable for preparing recombinant plasmids of the present invention for completely cellular expression of a Nidovirales virus is the plasmid pCMVbeta (Clontech, Palo Alto, Calif., USA). Other plasmids which are able to transfect and express genes in eukaryotic cells which can be used to prepare plasmids of the present invention include, but are not limited to, pcDNA3.1, pRc/RSV, and pZeoSV2 (all from Invitrogen); and pCMV-Sports and pSV-Sport1 (both from Life Technologies Inc.). However, almost any eukaryotic expression vector will work for the present invention. Constructs based on cosmids can also be used for completely cellular ex vive expression of a Nidovirales virus.

Suitable host cells for the completely cellular method of the present invention for expressing PRRS virus include porcine alveolar macrophage cells and the MARC-145 cells, described above. Methods of transfecting these cells with a plasmid are basically the same as those methods for transfecting cells with viral ANA described above. Such methods include, but are not limited to, electroporation, lipofection, DEAE dextran mediated transfection, and calcium phosphate coprecipitation.

Once host cells, such as porcine alveolar macrophage cells or a MARC-145 cells, have been transfected according to the subject invention, either with viral RNA or with a plasmid comprising a nucleotide sequence encoding a virus, then the cells can be frozen at about −80° C. or below for storage for up to several years. For longer periods of time, i.e. decades, storage in liquid nitrogen is preferred. If relatively frequent use of the encoded virus is envisioned, then cells hosting the virus can also be maintained (unfrozen) in culture using known techniques, for shorter periods of time. Moreover, viral particles excreted by such cells can be stored frozen at about −80° C. or below as a source of virus. Transfection of such cell lines with the polynucleotide molecule encoding the virus can be confirmed if desired, for example, by testing exhausted medium excreted by the cell line for a PRRS virus antigen using an immunofluorescent antibody test. Antibodies which are specific for PRRS virus antigens are known in the art (see, e.g., Collins, E. J., et al., WO 93/03760 Mar. 4, 1993).

In another embodiment, a plasmid of the present invention comprising a nucleotide sequence encoding a North American PRRS virus is suitable for in vive expression of the North American PRRS virus, i.e. expression in a living organism. Plasmids which can be used for preparing recombinant plasmids for in vivo expression of a North American PRRS virus include, but are not limited to the plasmids capable of transfecting eukaryotic cells described above, such as pCMVbeta.

Animals that can be transfected with plasmids of the present invention include mammals and birds. If the animal is other than a porcine animal, for example, a mallard duck, then the plasmid can comprise a nucleotide sequence encoding a North American PRRS virus comprising further antigenic epitopes from pathogens which are capable of pathogenically infecting the animal; in such a case, the plasmid will encode a North American PRRS virus serving as a vector for transporting epitopes into the animal. If the animal is a porcine animal, then the plasmid can usefully encode any of the North American PRRS viruses described herein, including the genetically-modified North American PRRS viruses described herein.

E. Viral Vectors Encoding a North American PRRS Virus, Including Viral Vectors Encoding Genetically Modified North American PRRS Viruses:

The present invention also provides viral vectors comprising a DNA sequence encoding an infectious RNA molecule encoding any of the North American PRRS viruses described herein, including the genetically-modified North American PRRS viruses described herein. Such viral vectors are useful for transfecting eukaryotic cells for production of PRRS viruses of the present invention outside of a living organism, or for transfecting swine, or other mammals, or avians, with the sequence encoding the North American PRRS virus, for in vive expression of the North American PRRS virus therein.

Some examples of viruses that can be used as vectors for preparing the viral vectors of the present invention include, but are not limited to, swine viruses such as, but not limited to, swine pox virus, pseudorabies virus, or African swine fever virus. Such swine viruses can be obtained from The National Veterinary Services Laboratories (Ames, Iowa, USA) of the United States Department of Agriculture; the American Type Culture Collection, otherwise known as the ATCC (Manassas, Va., USA); and other known sources. Recombinant viral vectors based on suitable swine viruses such as the aforementioned swine viruses are useful for transfecting swine animals with a nucleotide sequence encoding a North American PRRS virus of the present invention.

Viral vectors comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus of the present invention based on these and other viruses can be prepared using known recombinant techniques described in texts such as those cited previously in this application.

F. Transfected Host Cells Encoding or a Genetically Modified North American PRRS Viruses.

The present invention also provides transfected host cells that comprise a DNA sequence encoding an infectious RNA molecule encoding any of the North American PRRS viruses described herein, including the genetically-modified North American PRRS viruses described herein, which transfected host cells are capable of expressing the North American PRRS virus. Such transfected host cells are useful for producing North American PRRS viruses of the present invention. Examples of transfected host cells of the present invention include the transfected porcine alveolar macrophage cells and the transfected MARC-145 cells described above.

Other transfected host cells of the invention include, but are not limited to, transfected MA-104 cells and other derivatives of MA-104 cells that are transfected; transfected Baby Hamster Kidney (BHK) cells; transfected Chinese Hamster Ovary (CHO) cells; and African Green Monkey kidney cells other than MA-104 cells or MARC-145 cells, such as VERO cells; that are transfected.

G. North American PRRS Viruses, Including Genetically Modified North American PRRS Viruses:

The present invention also provides North American PRRS viruses as described herein, including genetically-modified North American PRRS viruses as described herein, expressed and/or encoded by any of the above-described isolated polynucleotide molecules, RNA molecules, plasmids, viral vectors, or transfected host cells.

In certain situations, for example where the North American PRRS virus is to be used in a vaccine for swine and the North American PRRS virus has not been genetically modified as described above so as to be unable to cause PRRS, it is desirable to treat the North American PRRS virus, for example by inactivating or attenuating it, so that it is unable to cause PRRS in swine to which it is administered. Known methods can be used to inactivate a North American PRRS virus of the present invention so that it is unable to cause PRRS in an animal. Examples of such methods include, but are not limited to, treatment with formaldehyde, BEI (binary ethyleneimine), or BPL (beta-propiolactone). Methods of attenuation are also known in the art, and such methods can be used to attenuate a North American PRRS virus of the present invention. A North American PRRS virus of the present invention can, for example, be attenuated by serial passage in cell culture.

If a North American PRRS virus of the present invention is for use in an animal other than a porcine animal, or if it has been genetically modified as described herein so that it is unable to produce PRRS in a porcine animal, then it is not necessary to treat the virus as described in the preceding paragraph prior to using it in a vaccine.

The following examples are provided to merely illustrate aspects of the subject invention. They are not intended, and should not be construed, to limit the invention set forth in the claims and more fully described herein.

EXAMPLES Example 1 Preparation of an Infectious cDNA Clone of a North American PRRS Virus Isolate

Source of PRRS Virus and MARC-145 Cells:

A North American PRRS virus isolate designated P129 was obtained from Drs. Gregory W. Stevenson, William G. Van Alstine, and Charles L. Kanitz of Purdue University's Animal Disease Diagnostic Laboratory in West Lafayette, Ind. The P129 virus was originally isolated in the autumn of 1995 from a swine herd in southern Indiana experiencing a severe PRRS outbreak. This farm had no previous history of PRRS problems or PRRS vaccination. The P129 isolate was more virulent than several other field isolates from the same time period and geographic area, in that it produced more severe and more consistent respiratory disease in young pigs. The virus was initially isolated on primary porcine alveolar macrophage (the natural host cell), and subsequently passaged on MARC-145 cells (Kim et al., 1993). Genes encoding structural proteins of P129 were found to be homologous to corresponding known North American PRRS gene sequences.

The MARC-145 cell line that was used to propagate PRRS viruses is a clone of the MA-104 Rhesus Macaque Monkey Kidney cell line. The MARC-145 cells were obtained from the National Veterinary Services Laboratories (NVSL, Ames, Iowa) of the USDA. These cells have been tested and found negative for mycoplasmas and for common porcine extraneous agents. MARC-145 cells are routinely grown at 37 C. in OptiMEM (Life Technologies Inc.) with 2% fetal bovine serum and antibiotics.

Five biological clones were plaque purified from the P129 virus stock, and these were designated P129A through P129E. Plaque purification was carried out by infecting monolayers of MARC-145 cells with P129 virus, adding an overlay of OptiMEM containing 1.25% SeaPlaque agarose (FMC BioProducts), 2% fetal bovine serum, and antibiotics. Plaques were clearly visible following incubation for 7 days, when 5 well-isolated plaques were picked and passaged onto fresh MARC-145 monolayers. When cytopathic effect (virus induced cell death) became apparent the progeny virus from each of these cultures was subjected to another round of plaque purification. One well-isolated plaque from each of the five clones was picked and expanded to produce large stocks. The 5 clones were tested for virulence in young pigs, either individually (clones A and E) or in combination (clones B-D, or clones A-E). In all cases, the plaque purified virus replicated well in pigs and caused clinical disease. The severity of clinical symptoms was less than that caused by the uncloned P129 virus, even when all five clones were used together. P129A was chosen for sequencing, and was used in subsequent molecular manipulations.

Determination of the Genome Sequence of P129A:

Plaque purified virus P129A was used for sequence determination after 10 serial passages from the pig (including two plaque purifications and one subsequent passage). SEQ ID NO:1 shows the cDNA sequence corresponding to the P129A RNA genome. The genome is 15,395 nucleotides in length (excluding the polyadenosine tail), begins with ATGACGTA, and ends with CCGCAATT. A typical polyadenosine tail of 55 residues is also provided in SEQ ID NO:1.

For the structural genes of P129A (ORFs 2 through 7), which comprise the 3′ 20% of the genome, various PCR primers were chosen based on several partial cDNA sequences of other North American PRRS virus isolates available in the public DNA sequence database GenBank (for example PRU00153). Purified viral RNA was reverse transcribed into cDNA using reverse transcriptase and random hexamer primers. This cDNA was then used in PCR with gene-specific primers. PCR products were excised from gels and T/A cloned into plasmid pCR2.1 (Invitrogen). For each primer pair, multiple plasmids (from independent PCR reactions) were DNA sequenced. Sequences were assembled using the Seqman program from the Lasergene package (DNASTAR, Inc). This permitted completing the sequence of positions 11,992 through 15,347 of the P129A genome.

Also in the GenBank database are a series of short sequences (approximately 218 nucleotides total) which comprise a portion of the ORF 1b gene of several isolates of PRRS virus. One of these (PPSSEQB) was used to design PCR primers (forward 5′-ACAGTTTGGTGATTATG-3′ (SEQ ID NO:10), corresponding to positions 9063-9080; reverse 5′-CAGATTCAGATGTTCAA-3′ (SEQ ID NO: 1), corresponding to positions 9252-9268). These amplified a 206 nucleotide fragments, which includes 171 nucleotides of new sequence from the P129A ORF1b gene, corresponds to positions 9081 to 9251. A new forward primer was designed within this region (5′-ACCTCGTGCTGTATGCOGAATCTC-3′ (SEQ ID NO:12), positions 9201-9224), and a matching primer was designed within ORF1b immediately upstream of ORF2 (5′-TCAGGCCTAAAGTTGGTTCAATGA-3′ (SEQ ID NO:13), positions 12,027-12,050). These primers were used in RT-PCR to amplify a 2850 nucleotide fragment of ORF1b, corresponding to positions 9201-12,050 of the P129A genome.

During RT-PCR amplification of ORF5 of another North American field isolate of PRRS virus, a minor band was seen which was smaller than the expected size. This was sequenced and found to have limited homology with ORF1a of Lelystad virus (resulting from false priming). New primers within this region were chosen to amplify P129A (forward 5′-GATGACTGGGCTACTGACGAGGAT-3′ (SEQ ID NO:14), corresponding to positions 1587-1610; reverse 5′-AGAGCGGCTGGGATGACACTG-3′ (SEQ ID NO:15), corresponding to positions 1877-1897). In addition to the product of 311 nucleotides (266 nucleotides of new P129A sequence between the primers corresponding to positions 1611-1876), a larger minor PCR product of 701 nucleotides was cloned and sequenced (656 nucleotides of new P129A sequence between the primers corresponding to positions 1611-2264). The larger band results from false priming of the reverse primer at positions 2265-2269.

The extreme 5′ end of the genome of P129A was determined by 5′ RACE (rapid amplification of cDNA ends) using a commercially available kit (Life Technologies Inc). Two nested reverse primers were chosen from within the known ORF1a sequence (“RACE2” 5′-CCGGGGAAGCCAGACGATTGAA-3′ (SEQ ID NO:18), positions 1917-1938; and “RACE3” 5′-AGGGGGAGCAAAGAAGGGGTCATC-3′ (SEQ ID NO:17), positions 1733-1756). RACE2 was used to prime cDNA synthesis, while RACE3 was used in PCR. The resulting PCR products were cloned and sequenced. The two longest products ended at precisely the same base (position 1 in SEQ ID NO:1).

The large gap between known sequence in ORF1a and ORF1b was bridged using long RT-PCR. Two new primers were used (forward 5′-AGCACGCTCTGGTGCAACTG-3′ (SEQ 10 NO:18), positions 1361-1380; reverse 5′-GCCGCGGCGTAGTATTCAG-3′ (SEQ ID NO:19), positions 9420-9438). The resulting 8078 nucleotide RT-PCR product was cloned and sequenced.

The extreme 3′ end of the genome of P129A was determined by ligating the 3′ and 5′ ends of the viral RNA together and using RT-PCR to amplify the junction fragment. The resulting junction fragments were cloned and sequenced. Briefly, RNA extracted from pelleted virions was treated with tobacco acid pyrophosphatase (to remove 5′ cap structures), then self-ligated with T4 RNA ligase (both from Epicentre Technologies). The primers used were 5′-CGCGTCACAGCATCACCCTCAG-3′ (SEQ ID NO:20) (forward, positions 15,218-15,239) and either 5′-CGGTAGGTTGGTTAACACATGAGTT-3′ (SEQ ID NO:21) (reverse, positions 656-680) or 5′-TGGCTCTTCGGGCCTATAAAATA-3′ (SEQ ID NO:22) (reverse, positions 337-359). All of the resulting clones were truncated at the 5′ end of the genome (the most complete came to within 57 nucleotides of the actual 5′ end, as revealed by 5′ RACE), however two of these clones contained the complete 3′ end of the genome including the polyadenosine tail (42 and 55 adenosine residues in length). This completed the sequencing of the cDNA 15,450 base genome of PRRS isolate P129A, including polyA tail, as shown in SEQ ID NO:1.

Creation of an Infectious Full-Length cDNA Clone of P129A:

A full-length infectious cDNA clone of P129A, designated pT7P129A, was assembled from four overlapping cloned RT-PCR products. The four RT-PCR products were first T/A cloned into plasmid pCR2.1 (Invitrogen) and transfected into Escherichia coli strain DH5-alpha. Bacterial colonies were screened, and those which contained inserts of the expected sizes in the “T7 to M13” orientation were chosen for sequencing and further manipulation. All four cloned RT-PCR products contained one or more non-silent mutations (deviations from the consensus nucleotide sequence for P129A of SEQ ID NO:1 which would result in a change in amino acid sequence of the encoded ORFs). These non-silent mutations (save one at position 12,622 in ORF 2) were repaired by subcloning fragments from other cloned RT-PCR products. The four repaired subgenomic clones were assembled into a full-length clone in a stepwise manner, using available restriction sites (see FIG. 1). The 5′ and 3′ ends of the cDNA corresponding to the P129A genome in pT7P129A were modified by the addition of a T7 promoter and appropriate restriction endonuclease sites. The construction of pT7P129A is described in further detail in the following paragraphs:

The 5′ end of the genome (positions 1-1756), generated by 5′-RACE and cloned into pCR2.1 as described above, was modified to include a T7 promoter immediately upstream of the cDNA corresponding to the P129A genome and a PacI site for future cloning. A 3-way ligation was performed using the 1216 bp DsaI-BseRI fragment of this plasmid (containing bases 27-1242 of P129A), the 4407 bp BseRI-XbaI fragment of the same plasmid (containing bases 1243-1756 of P129A and the entire plasmid vector up to the XbaI site), and the following synthetic double-stranded adapter (SEQ ID NO: 23, first below and SEQ ID NO; 24, second below):

5′-CTAGATTAATTAATACGACTCACTATAGGG ATGACGTATAGGTGTTGGCTCTATGC-3′ 3′-TAATTAATTATGCTGAGTGATATCCC XbaI_____     T7 promoter           PacI TACTGCATATCCACAACCGAGATACGGTGC-5′ _________________________DsaI  P129A genome

The predicted transcript from the 17 promoter includes a single “G” residue from the promoter immediately upstream of the first “A” of the viral genome. A non-silent mutation at position 1230 (A to G) was repaired by replacing the 906 bp AatII—SacII fragment (bases 740-1645) with the same fragment from another clone. This plasmid was designated “pT7R3A-2”.

The 8078 nucleotide PCR product described above was used to cover bases 1361-9438 of the P129A genome. A 58 bp deletion (positions 2535-2592) and 7 non-silent point mutations were corrected by subcloning fragments from other cloned RT-PCR products, yielding plasmid “pGAP10B-4”. The 7837 bp Bsu36I-SpeI fragment from this plasmid was ligated to the 5482 bp Bsu36I-SpeI fragment from pT7R3A-2. The resulting plasmid “pT7RG” contains the first 9438 bases of the P129A genome behind the T7 promoter.

The 2850 nucleotide fragment of ORF1b described above (genome positions 9201-12,050) was corrected to repair non-silent mutations and designated “p1B3A-2”. The 2682 bp NdeI-SpeI fragment of this plasmid was ligated to the 13,249 bp NdeI-SpeI fragment of pT7RG to yield plasmid “pT71A1B”, which contains the first 12,050 bases of the P129A genome.

The fourth and final fragment of the P129A genome was derived by RT-PCR of ORFs 2 through 7, including the 3′ non-translated region and a portion of the polyA tail. The forward primer was 5′-ACTCAGTCTAAGTGCTGGAAAGTTATG-3′ (SEQ ID NO:25) (positions 11,504-11,530) and the reverse primer was 5′-GGGATTTAAATATGCATTTTTTTTTTTTTTT TTTTTTAATTGCGGCGGCCGCATGGTTCTCG-3′ (SEQ ID NO:26). The reverse primer contains the last 22 bases of the P129A genome (positions 15,374-15,395), a polyA tail of 21 bases, an NsiI site (ATGCAT) and a SwaI site (ATTTAAAT). Non-silent point mutations and a single base deletion were repaired by subcloning fragments from other clones. An additional non-silent point mutation at position 12,622 (A to G) was inadvertently introduced at this stage. This results in a change from glutamine to arginine near the C-terminus of the ORF2 protein (amino acid residue 189 of the 256 amino acids in ORF2, which does not affect the overlapping ORF 3). This mutation had no apparent influence on viral growth, in cell culture or in pigs, and was not repaired. This mutation served as a genetic marker to distinguish virus derived from the cDNA clone from possible contamination with parental P129A or other PRRS viruses. The plasmid was designated “p2_(—)7D-4”. The structural genes of P129A were added to the rest of the genome by ligating the 3678 bp Eco47III-SpeI fragment of p2_(—)7D-4 to the 15.635 bp Eco47III-SpeI fragment of pT71A1B.

This yields the final construct “pT7P129A”, which comprises cDNA corresponding almost identically to the entire genome of P129A (however, with only a 21 base polyA tail, as opposed to 55 base potyA tail) behind a T7 promoter, cloned into the pCR2.1 vector between unique restriction enzyme sites (PacI and SwaI). The total length of pTP7129A is 19,313 bp, and it is stable in E. coli strain DH5-alpha. pT7P129A contains an A to G non-silent point mutation at position 12,622 that results in an arginine at position 189 of ORF2 rather than a glutamine (as is encoded by SEQ ID NO:1) and a silent C to T mutation at position 1559. Neither of these mutations affected viral growth under the conditions examined, both in cell culture and in pigs. For example, pT7P129A was used for in vitro transcription and the resulting RNA transcripts produced live North American PRRS virus when transfected into MARC-145 cells, thus demonstrating that this full-length clone is infectious.

In Vitro Transcription and Transfection of RNA Transcripts:

In plasmid pT7P129A there are two T7 promoters in tandem upstream of the viral genome. One of these is positioned immediately upstream of the viral genome and was built into the PCR primer as described above. The other is present in the pCR2.1 cloning vector and is located outside of the multiple cloning site (initiating transcription 44 bases upstream of the viral genome). PacI was used to cut between these T7 promoters prior to in vitro transcription to generate a transcript that is closer to authentic viral RNA (a single extra G immediately upstream the viral genome, as opposed to 44 extra bases from the distal T7 promoter). In addition, pT7P129A was cut with SwaI prior to in vitro transcription. The resulting run-off transcripts include a 21 base long polyA tail and nine non-PRRS nucleotides, including an Ns site (which was not used to linearize the plasmid, since the site also occurs once in the viral genome). The digested plasmid was purified by phenol extraction and ethanol precipitation prior to use.

A commercial kit (T7 Cap-Scribe, Boehringer Mannheim) was used for in vitro transcription. The DNA pellet from above, containing about 0.6 μg of PacI/SwaI digested pT7P129A, was resuspended in 20 μl of T7 Cap-Scribe buffer/T7 polymerase and incubated at 37° C. for 30 minutes. A portion of the reaction was analyzed by agarose gel electrophoresis and shown to contain full-length RNA transcripts in addition to the expected DNA bands of 15,445 bp and 3868 bp. The in vitro transcription reaction was used fresh, immediately following incubation, without purification. Freshly confluent monolayers of MARC-145 cells were washed once in OptiMEM (without serum), and covered with 1 ml per 35 mm well of OptiMEM (without serum) containing 500 μg/ml DEAE dextran (molecular weight approx. 500,000, Pharmacia Biotech). In vitro transcription reaction (15 μl) was added immediately. After 1 hour at 37° C., the transfection mixture was removed, monolayers were washed once with PBS and overlaid with 1.25% SeaPlaque agarose (FMC corporation) in OptiMEM with 2% fetal bovine serum and antibiotics. After 5 days at 37° C., a single plaque was visible. This virus was designated “rP129A-1” and was expanded on MARC-145 cells and characterized in cell culture and in pigs. Subsequent transfections of in vitro transcribed RNA from pT7P129A, using both DEAE dextran and electroporation, have yielded many additional plaques.

Characterization of Recombinant Virus rP129A-1:

There are no apparent differences in growth kinetics, yield, or plaque morphology between cDNA-derived recombinant virus rP129A-1 and its non-recombinant parent P129A. As discussed above, there are two differences in nucleotide sequence between the coding sequence of pT7P129A and the consensus sequence of P129A (shown in SEQ ID NO:1). Firstly, at position 1559 pT7P129A contains a T, whereas P129A contains a C (this is a silent mutation). Secondly, at position 12,622 pT7P129A contains a G, whereas P129A contains an A (this is the glutamine to arginine change in ORF2 described above). In order to rule out the possibility that rP129A-1 is actually a non-recombinant PRRS virus contaminant, RT-PCR and sequencing were performed on the regions surrounding these two differences in the case of both genetic markers, rP129A-1 was identical to plasmid pT7P129A and different from parental virus P129A, thus confirming that rP129A-1 is derived from the infectious cDNA clone.

Characterization of Recombinant Virus rP129A-1 in Pigs:

The cDNA-derived virus rP129A-1 was compared to its non-recombinant parent P129A for its ability to infect and cause clinical disease in young pigs. Three groups of 10 pigs each from a PRRS-negative herd were infected at 4 weeks of age with either P129A, rP129A-1, or mock-infected with cell culture medium. Clinical signs, rectal temperatures, and body weights were monitored. Blood was collected on days 0, 2, 6, 10, and 13 post-infection for determination of serum viremia (by plaque assay on MARC-145 cells, FIG. 2) and serum antibody (by ELISA using HerdChek PRRS from IDEXX, FIG. 3). Gross and microscopic lesions of the lung were observed upon necropsy. There were no significant differences between the two virus-infected groups, indicating that rP129A-1 replicates in pigs and causes clinical disease which is quantitatively and qualitatively similar to its non-recombinant parent virus.

Example II Deletion of ORF7 (Nucleocapsid Gene) from the North American PRRS Virus; Preparation of a Negatively-Marked, Replication-Defective Vaccine Thereby

The viral nucleocapsid gene (ORF7) was partially deleted from an infectious cDNA clone of the PRRS virus of the present invention. The resulting recombinant modified PRRS virus would be expected to be replication-defective in pigs. This recombinant modified PRRS virus can be used as a vaccine to induce an immune response to the other PRRS virus proteins without the risks of clinical disease, spread to non-vaccinated animals, or reversion to virulence associated with attenuated live vaccines. In addition to being very safe, such a vaccine virus would also be “negatively marked”, in the sense that it would allow exposure to field isolates of PRRS virus to be determined serologically, even in the presence of antibody to the vaccine virus. Antibodies to the ORF7 protein are commonly found in the sera of PRRS virus-infected pigs, whereas pigs vaccinated with an ORF7-deleted PRRSV would lack antibodies to the ORF7 protein.

Deletion of ORF7 from an infectious clone was accomplished as follows: Plasmid p2_(—)7D-4 (see FIG. 1) was used as template in PCR to amplify the 5′ and 3′ flanking regions upstream and downstream of ORF7. The upstream flank forward primer 5′-ATTAGATCTTGC CACCATGGTGGGGAAATGCTTGAC-3′ (SEQ ID NO:27) (which binds to genome positions 13,776-13,791 near the beginning of ORF5 and contains additional restriction sites which are irrelevant to the current cloning) and the upstream flank reverse primer 5′-CTTTACGCGTTTG CTTAAGTTATTTGGCGTATTTGACAAGGTTTAC-3′ (SEQ ID NO:28) (which binds to genome positions 14,857-14,902 at the junction of ORFs 6 and 7) amplified a fragment of 1147 bp. The reverse primer introduced MluI and AflII sites and a single base change at position 14,874, destroying the ATG start codon for ORF7 without altering the tyrosine encoded in the overlapping ORF6. For the downstream flank, the forward primer 5′-CAACAC GCGTCAGCAAAAGAAAAAGAAGGGG-3′ (SEQ ID NO:29) (positions 14,884-14,914 near the 5′ end of ORF7, introduced an MluI site) and reverse primer 5′-GCGCGTTGGCCGATTC ATTA-3′ (SEQ ID NO:30) (downstream of the viral genome in the pCR2.1 plasmid) amplified a 462 bp fragment. A 3-way ligation was performed, using the 611 bp BstEII-MluI fragment of the upstream flank PCR product, the 575 bp MluI-SpeI fragment of the downstream flank PCR product, and the 8653 bp BstEII-SpeI fragment from plasmid p2_(—)7D-4 (all fragments were gel purified following digestion). The resulting plasmid p2_(—)7Ddelta7+7023 was deleted in the first seven amino acids of ORF7, and lacks a functional ATG start codon. Two new restriction sites which are absent in both the viral genome and the plasmid backbone, AlfII and MluI, have been inserted to facilitate directional cloning of foreign genes into the space previously occupied by the 5′ end of ORF7.

The changes made in p2_(—)7Ddelta7+7023 were incorporated into a full-length genomic clone by ligating the 3683 bp Eco47III-SpeI fragment of p2_(—)7Ddelta7+7023 with the 15,214 bp Eco47III-SpeI fragment of pCMV-S-p129. The resulting plasmid pCMV-S-p129delta7+7023 was used to transfect cells.

Since nucleocapsid is essential for viral growth, it is necessary to provide this protein in order to allow generation and replication of an ORF7-deficient PRRS virus. This can be accomplished using a helper virus or a complementing cell line, for example. ORF7-expressing MARC-145 cell lines can be created by stably transfecting cells with a plasmid containing both the ORF7 gene from P129A and the neomycin resistance gene. After selecting for neomycin resistance using the antibiotic G418, single-cell colonies can then be expanded and characterized. Clonal MARC-145-derived cell lines that are positive for ORF7 expression by both immunofluorescence and RT-PCR can be transfected with RNA from pT7P129delta7 in order to generate ORF7-deficient P129 virus.

Similar strategies can be used to generate PRRS viruses deficient in other structural genes (ORFs 2, 3, 4, 5, or 6), or deficient in all or portions of non-structural genes 1a and 1b. In addition, multiple deletions can be engineered into a single PRRS virus, and these can be grown in complementing cells which provide all necessary functions. Such gene-deficient PRRS viruses are likely to be either partially or completely attenuated in pigs, making them useful as vaccines against PRRS. They can also be used to distinguish vaccinated animals from animals infected with a wild-type PRRS virus as discussed above and/or as vectors for vaccinating animals with epitopes of other porcine pathogens (see Example III, below).

Example III Insertion of Heterologous Genes into the North American PRRS Virus Genome; Use of PRRS Virus as a Vector, and a Positively-Marked North American PRRS Virus

In Example II, above, AflII and MluI restriction enzyme sites were inserted into the region formerly occupied by the 5′ end of ORF7. These sites are absent in the P129A genome and in the pCR2.1 and pCMV plasmids, and can be used in the directional cloning of foreign (heterologous) genes into the viral genome for expression. Potential leader-junction sites for transcription of the ORF7 subgenomic RNA at positions 14,744-14,749 (ATAACC) and 14.858-14,863 (TAAACC) are not affected by deletion of the ORF7 coding sequence, and can function in transcription of a foreign gene. Foreign (heterologous) genes can include genes from other PRRS virus isolates or genotypes, and/or genes from other non-PRRS pathogens, either pathogens that infect swine or pathogens that infect mammals other than swine, or avians.

In addition, these foreign genes (or portions thereof) can provide antigenic epitopes which are not normally found in swine. Such epitopes can be used to “positively mark” a vaccine, so that successful vaccination can be monitored serologically, even in the presence of antibody to field or conventional vaccine strains of PRRS virus. A positive marker needs not be a separate expression cassette. An antigenic epitope can be fused to a structural gene of the PRRS virus. For example, the upstream flank reverse primer described in Example I, above, can be extended in such a way as to add a carboxyl-terminal fusion of a non-PRRS virus antigenic epitope to the ORF6 membrane protein. The presence of antibody to this epitope in swine indicates successful vaccination.

Example IV Cellular Expression of a PRRS Virus by Direct Transfection of cDNA into Cells

The eukaryotic expression vector pCMV-MC1 (SEQ ID NO:31) was derived from the commercially available plasmid pCMVbeta (Clontech) by replacing the LacZ coding sequence between two Not I sites with a linker containing Not I, EcoR V, Avr II, Bgl II, Cla I, Kpn I, Pac I, Nhe I, Swa I, Sma I, Spe I and Not I sites. Modification of the human CMV immediate early promoter was accomplished by substituting the sequence between the Sac I and the second Not I sites of pCMV-MC1 with a synthetic linker (shown below). The linker contains a half site for Sac I following by Pac I, Spe I and a half site for Not I. After annealing the two single stranded oligonucletides, the linker was cloned into pCMV-MC1 between the Sac I and Not I sites, and a selected clone was designated pCMV-S1. The Spa I site of pCMV-S1 could not be cut, possibly due to a mistake in the oligo sequence. Therefore, the fragment between Pac I and Hind III in pCMV-S1 was replaced with Pac I (at position 877)-Hind III (at position 1162) fragment from pCMV-MC1. Thus, a Spe I site was regained. This final construct (pCMV-S) was used to clone the full length P129 genome.

Linker sequence (SEQ ID NO: 32, first below and SEQ ID NO: 33, second below):

5′CGTTAATTAAACCGACTAGTGC 3′ 3′ TCGAGCAATTAATTTGGCTGATCACGCCGG 5′  _______   PacI         SpeI____     SacI                      NotI

The sequence immediately upstream of the 5′ end of the P129 genome was modified to contain proper spacing and a convenient restriction enzyme site (Pac I). This was done by designing appropriate PCR primers (SEQ ID NO:34 and SEQ ID NO:35) for amplification from pT7P129. After digestion with Pac I and Aat II, this PCR fragment was subcloned into the Pac I and Aat II sites of pT7RG (FIG. 1). The resulting plasmid was designated pT7RG-deltaT7.

The final construction was completed by subcloning the viral sequences from pT7RG-deltaT7 at the Pac I and Nde I sites into pT7P129, creating pT7P129-deltaT7. The full length P129 genome was digested from pT7P129-deltaT7 at Pac I and Spa I and transferred into pCMV-S at the Pac I and Spa I sites. This constructed was named pCMV-S-P129.

The sequence of the region of modification between the CMV promoter TATA box and the 5′ end of the P129 sequence in pCMV-S-P129 is shown in SEQ ID NO:36 and schematically presented below:

   TATATAAGCAGAGCTCGTTAATTAAACCGTC  5′ TATA box   SacI  PacI ATGACGTATAGGTGTTGGC Start of P129 3′

To test the use of the CMV promoter to initiate PRRS virus infection in cells, pCMV-S-P129 plasmid DNA (0.5 or 1.0 μg) was transfected into MARC-145 cells by lipofection using Lipofectamine™ (Life Technologies Inc.). PRRS virus specific cytopathic effect was observed after transfection and the presence of PRRS virus antigen was determined by the immunofluorescent antibody test.

PRRS virus was generated efficiently from pCMV-S-P129, and the progeny virus can be passaged on MARC-145 cells. This demonstrates that a PRRS virus infection can be initiated directly from a plasmid cDNA encoding a PRRS virus, without an in vitro transcription step. Furthermore, pCMV-S-P129 generated a greater amount of progeny virus compared to plasmids wherein the 3′ end of the pCMV promoter was not immediately in front of the start of the sequence encoding the North American PRRS virus.

Example V Deletion of ORF4 from the North American PRRS Virus: Preparation of a Replication-Defective Vaccine Thereby

A portion of the gene for ORF4, which encodes a membrane glycoprotein, was deleted from an infectious cDNA clone of the PRRS virus of the present invention. The resulting recombinant modified PRRS virus is expected to be replication-defective in pigs and to induce an immune response to the other PRRS virus proteins without the risks of clinical disease, spread to non-vaccinated animals, or reversion to virulence associated with attenuated live vaccines.

Deletion of ORF4 from an infectious clone was accomplished as follows. Plasmid p2_(—)7D-4 (see FIG. 1) was used as template in PCR to amplify the 5′ and 3′ flanking regions upstream and downstream of ORF4. The upstream flank forward primer was 5′-AGGTCGAC GGCGGCAATTGGTTTCACCTAGAGTGGCTGCGTCCCTTCT-3′ (SEQ ID NO:37). This primer binds to genome positions 13194-13241, near the beginning of ORF4, and introduces a mutation at position 13225 which destroys the ATG start codon of ORF4 without altering the overlapping amino acid sequence of ORF3. The upstream flank reverse primer was 5′-TCTTAAGCATTGGCTGTGATGGTGATATAC-3′ (SEQ ID NO:38). This primer binds to genome positions 13455-13477 within the ORF4 coding region, downstream of ORF3, and introduces an AflII site. For the downstream flanking region, the forward primer was 5′-CTTC TTAAGTCCACGCGTTTTCTTCTTGCCTTTTCTATGCTTCT-3′ (SEQ ID NO:39). This primer binds to genome positions 13520-13545 in the middle of ORF4, and introduces AflII and MluI sites for directional cloning of foreign genes. The reverse primer was 5′-TGCCCGGTCCCTT GCCTCT3′ (SEQ ID NO:40). This primer binds to genome positions 14981-14999 in the ORF7 coding sequence. A three-way ligation was performed using the SalI-AflII fragment of the upstream flank PCR product, the AflII-BsfEII fragment of the downstream flank PCR product, and the SalI-BstEII fragment from plasmid p2_(—)7D-4. All fragments were gel-purified following digestion. The resulting plasmid p2_(—)7D-4-delta4N has 42 bases of the central portion of ORF4 deleted and replaced with a 15 base artificial cloning site. The cloning site contains two restriction sites (AflII and MluI) that are absent from both the viral genome and the plasmid backbone. These can be used to facilitate directional cloning of foreign genes into the space previously occupied by ORF4. The cloning site also contains a stop codon (TAA) that is in frame with ORF4 and further assures that functional ORF4 protein is not produced.

It was found that a more extensive deletion of the ORF4 coding sequence can be made without interfering with expression of the downstream ORF5 envelope gene. In this case a shorter downstream flanking region was amplified by PCR using the same template and reverse primer, and using forward primer 5′-GTTTACGCGTCGCTCCTTGGTGGTCG-3′ (SEQ ID NO:41). This primer binds to genome positions 138654-13669 near the 3′ end of ORF4, and contains an AflII site. Two-way ligation between the AflII-BstEII fragment of the downstream flank PCR product and the AflII-BstEII fragment from plasmid p2_(—)7D-4-delta4N yielded the new plasmid p2_(—)7D-4-delta4NS. This plasmid has 176 bases of the ORF4 coding sequence deleted and replaced with the 15 base cloning site.

The changes made in p2_(—)7D-4-delta4N and p2_(—)7Ddelta4NS were incorporated into the full-length genomic clone by replacing the BsrGI-SpeI fragment from pCMV-S-P129 with the modified BsrGI-SpeI fragments from p2_(—)7D-4-delta4N and p2_(—)7D-4-delta4NS. The resulting plasmids pCMV-S-P129delta4N and pCMV-S-P129delta4NS were used to transfect cells.

In contrast to pCMV-S-P129, transfection of MARC-145 cells with plasmids pCMV-S-P129delta4N or pCMV-S-P129delta4NS did not result in viral plaques or fluorescent foci, Individual transfected cells can be seen to be producing the ORF7 nucleocapsid protein, suggesting that the ORF4 gene product is not required for RNA replication or expression of viral genes, but is essential for release of infectious progeny virus. Since deletion of ORF4 is lethal to virus replication, it is necessary to provide this protein. This can be accomplished by using a complementing cell line. We created ORF4-expressing MARC-145 cell lines by stable transfecting cells with a plasmid containing both ORF4 and the neomycin resistance gene. After selection for neomycin resistance using the antibiotic G418, single-cell colonies were expanded and characterized. After transfection with pCMV-S-P129delta4NS, three ORF4-expressing cell clones yielded live virus that can be propagated in these cells but not in MARC-145 cells. One of these, MARC400E9, was further characterized. Immunofluorescent staining for viral nucleocapsid in MARC400E9 cells transfected with plasmid pCMV-S-P129delta4NS was positive.

Virus derived by transfecting MARC400E9 cells with the pCMV-S-P129delta4NS plasmid (designated P129delta4NS) was amplified by passaging several times on MARC400E9 cells and was used to vaccinate pigs against a virulent PRRSV challenge. Live virus was formulated with one of three different types of adjuvant or used without adjuvant, and was delivered in two doses by one of two vaccination routes (intranasal followed by intramuscular, or intramuscular followed by a second intramuscular dose).

At approximately three weeks (Day 0) and five weeks (Day 14) of age, seroenegative conventional pigs were vaccinated according to the Table 2, below. The pigs in Group J were considered sentinel pigs and were necropsied approximately one week prior to challenge to evaluate the health status of all pigs.

TABLE 2 Test groups selected for vaccination derived from P129delta4NS Group Vaccine N Route* Adjuvant A P129delta4NS 10 IN/IM None B P129delta4NS 10 IM/IM None C P129delta4NS 10 IN/IM rmLT** D P129delta4NS 10 IM/IM rmLT E P129delta4NS 10 IN/IM QuilA/Cholesterol F P129delta4NS 10 IM/IM QuilA/Cholesterol G P129delta4NS 10 IN/IM Amphigen H P129delta4NS 10 IM/IM Amphigen I PBS only 10 IM/IM None J None 10 NA NA *IN—intranasal; IM—intramuscular. **recombinant mutant heat-labile enterotoxin from E. coli.

The first and second intramuscular vaccinations were administered in the left and right sides of the neck, respectively, On Days 0, 13, 21 and 28, blood samples were collected for serology (IDEXX HerdChek PRRS ELISA). At approximately three weeks following the second vaccination (Day 35), all pigs were challenged with 1 mL of parental P129 virus instilled drop-wise in each nostril (a total of 2 mL/pig or 1.2×10⁶ pfu), On Days 35, 38, 42 and 45, blood samples were collected from all pigs for serology and for PRRSV titration (by TCID50 assay). On Days 45 and 46, pigs were euthanized and necropsied. Lungs were removed from the chest cavity, examined for PRRS lesions, and photographed. Necropsies were performed at the Animal Disease Research and Diagnostic Laboratory (ADRDL) at South Dakota State University, Brookings, S. Dak.

The serological results showed induction of anti-PRRSV antibody in several of the vaccinated groups prior to challenge, and priming of the humoral immune system for a rapid post-challenge antibody response in all vaccinated groups. Immediately before challenge (Day 35), the average S/P ratio (Sample/Positive control ratio) value in the unvaccinated controls (group I) was 0.003. All eight of the vaccinated groups had higher values, ranging from 0.005 (group B) up to 0.512 (group H). By one week after challenge (Day 42), the control group was beginning to mount an antibody response to the challenge virus (S/P value of 0.171). All eight vaccinated groups had much higher antibody levels, ranging from 0.858 (group 8) to 1.191 (group G). This represents an increase in anti-PRRSV antibodies of approximately 5- to 10-fold as a result of priming of the humoral immune system.

TABLE 3 Anti-PRRSV antibody levels (S/P ratios) Day- Day- Day- Day- Day- Day- Day- Day- 1 13 21 28 35 38 42 45 Group None/IN 0.003 0.008 0.004 0.002 0.015 0.102 0.862 2.270 A Group None/IM 0.005 0.015 0.024 0.022 0.005 0.105 0.858 2.053 B Group rmLT/IN 0.002 0.030 0.015 0.021 0.016 0.108 1.219 2.653 C Group rmLT/IM 0.002 0.042 0.143 0.149 0.138 0.229 1.271 2.679 D Group QuilA/IN 0.015 0.039 0.084 0.048 0.013 0.097 1.217 2.299 E Group QuilA/IM 0.001 0.020 0.104 0.115 0.085 0.109 1.240 2.593 F Group Amph/IN 0.002 0.001 0.047 0.051 0.061 0.080 1.919 3.484 G Group Amph/IM 0.022 0.006 0.460 0.531 0.512 0.492 1.601 3.371 H Group PBS only 0.008 0.020 0.001 0.001 0.003 0.053 0.171 0.881 I

Following challenge with virulent PRRSV, serum viremia was determined. At three days post challenge (Day 38) the titer of virus in the unvaccinated control group had reached 2.58 logs. All eight of the vaccinated groups showed reduced viremia, ranging from 2.52 (group E) down to 1.07 logs (group H). This represents more than a 30-fold reduction in virus levels relative to the control group, see Table 4.

TABLE 4 Serum viremia (log 10 TCID50 titers) on day 38 (three days post challenge) Group A None/IN 2.18 Group B None/IM 1.98 Group C rmLT/IN 2.15 Group D rmLT/IM 2.48 Group E QuilA/IN 2.52 Group F QuilA/IM 1.65 Group G Amph/IN 1.74 Group H Amph/IM 1.07 Group I PBS only 2.58

At necropsy, all pigs were examined for the presence of macroscopic lung lesions resulting from the PRRS challenge virus. In the unvaccinated control group, 90% of the animals showed lung lesions. In contrast, all eight of the vaccinated groups showed reduced levels of lung lesions (ranging from 80% in group D down to 22% in group A). Vaccination reduces damage to the lungs that result from PRRSV infection. See Table 5.

TABLE 5 Number of pigs with macroscopic lung lesions/total pigs (percent positive) Group A None/IN  2/9 (22%) Group B None/IM 7/10 (70%) Group C rmLT/IN 6/10 (60%) Group D rmLT/IM 8/10 (80%) Group E QuilA/IN 5/10 (50%) Group F QuilA/IM 4/10 (40%) Group G Amph/IN 7/10 (70%) Group H Amph/IM  5/9 (56%) Group I PBS only 9/10 (90%)

The above swine data demonstrates the process of vaccinating swine with the recombinant North American PRRS virion containing the ORF 4 deletion. The results of the above data illustrate that the P129delta4NS virus, which is deleted in ORF4, is useful as a vaccine to protect pigs from disease caused by the PRRS virus. Efficacy of the vaccine may be increased by formulation with various adjuvants and by changing the route of administration.

Example VI Use of Gene-Deleted PRRS Virus as a Vector for Expression of Foreign Genes

In order to determine whether heterologous genes can be expressed from a gene-deleted PRRS virus, we inserted a copy of green fluorescent protein (GFP) into the site of ORF4 deletion in plasmid pCMV-S-P129delta4N. The GFP gene was amplified from a commercially available plasmid vector using PCR primers that introduced an AflII site at the 5′ end of the gene and an MluI site at the 3′ end of the gene. The resulting plasmid pCMV-S-P129delta4N-GFP was used to transfect MARC-145 and MARC400E9 cells. As anticipated, MARC-145 cells did not support replication of the ORF4-deleted virus. Single green cells resulting from primary transfection were seen under the UV scope, indication that GFP was being expressed, but the virus did not spread to neighboring cells and no CPE was observed. In contrast, large green foci were observed in transfected MARC400E9 cells. Visible plaques formed and merged, destroying the monolayer. These results indicate that foreign genes can be expressed from ORF4-deleted PRRS virus, and that increasing the size of the viral genome by 692 bases (4.5%) does not interfere with packaging of the viral RNA into infectious particles.

Example VII Use of Replication-Competent PRRS Virus as a Vector for Expression of Foreign Genes

In order to determine whether heterologous genes can be expressed from a replication-competent PRRS virus, we inserted a copy of GFP into the region between ORF1b and ORF2. Since the leader/junction (L/J) sequence for ORF2 lies within ORF1b, this L/J sequence was used to drive expression of the GFP gene and a copy of the ORF6 L/J sequence was inserted downstream from GFP to drive expression of ORF2.

Plasmid p2_(—)7D-4 (see FIG. 1) was used as template in PCR to amplify the 5′ and 3′ flanking regions upstream and downstream of the insertion site. The upstream flank forward primer was 5′-AACAGAAGAGAGTGTCGGGTCCAC-3′ (SEQ ID NO:42). This primer binds to genome positions 11699-11721 in ORF1b. The upstream flank reverse primer was 5′-GCTTT GACGCGTCCCCACTTAAGTTCAATTCAGGCCTAAAGTTGGTTCA-3′ (SEQ ID NO:43). This primer binds to genome positions 12031-12055 in ORF1b and adds AflII and MluI sites for directional cloning of foreign genes between ORF1b and ORF2. The downstream flank forward primer was 5′-GCGACGCGTGTTCCGTGGCAACCCCTTTAACCAGAGTTTCAGCGG AACAATGAAATGGGGTCTATACAAGCCTATACAAAGCCTCTTCGACA-3 (SEQ ID NO:44). This primer binds to genome positions 12056-12089 in ORF2 and contains an MluI site followed by the 40 bases that precede the start of ORF6 (containing the ORF6 L/J sequence). The downstream flank reverse primer was 5′-AACAGAACGGCACGATACACCACAAA-3′ (SEQ ID NO:45). This primer binds to genome positions 13819-13844 in ORF5. A three-way ligation was performed using the Eco47III-MluI fragment of the upstream flank PCR product, the MluI-BsrGI fragment from the downstream flank PCR product, and the Eco47III-BsrGI fragment from pCMV-S-P129. The resulting plasmid pCMV-S-P129-1bMCS2 contains the entire P129 genome with a cloning site and an additional L/J site between ORF1b and ORF2. The plasmid produces functionally normal virus when transfected into MARC-145 cells.

The GFP gene from a commercially available plasmid was PCR amplified using primers that add an AflII site to the 5′ end and an MluI site to the 3′ end of the gene. After digestion of the PCR fragment and PCMV-SP129-1bMCS2 with AflII and MluI, the insert was ligated into the vector to yield plasmid pCMV-S-P129-bGFP2. This plasmid produced green plaques when transfected into MARC-145 cells. The resulting virus can be passaged onto MARC-145 cells and continued to produce green plaques when observed under the UV scope. Thus, foreign genes may be expressed from replication-competent PRRS virus vectors. The P129-1bGFP2 virus contains a genome which is 774 bases (5%) longer than that of its P129 parent, yet it is packaged normally.

Example VIII Deletion of ORF 2 (Minor Structural Protein) from the North American PRRS Virus; Preparation of a Replication-Defective Vaccine

The following example illustrates the preparation of the North American PRRS virions containing the ORF 2 deletion.

The viral minor structural protein encoded by ORF2 is deleted from an infectious cDNA clone of the PRRS virus of the present invention. The resulting recombinant modified PRRS virus is replication-defective in pigs and can induce an immune response to the other PRRS virus proteins without the risks of clinical disease, spread to non-vaccinated animals, or reversion to virulence associated with attenuated live vaccines.

Deletion of ORF2 from an infectious clone was accomplished as follows. Plasmid p2_(—)7D-4 (see FIG. 1) was used as template in PCR to amplify the 5′ and 3′ flanking regions upstream and downstream of ORF2. The upstream flank forward primer was 5′-CAAAGGGC GAAAAACCGTCTATCA-3′ (SEQ ID NO:46), which binds within the cloning vector. The upstream flank reverse primer was 5′-CCCCACTTAAGTTCAAGTTCAATTCAGGC-3′ (SEQ ID NO:47), which binds to genome positions 12045-12067 near the beginning of ORF2. The downstream flank forward primer was 5′-GCTCCTTAAGAACAACGCGTCGCCATTGAAGCCGAGA-3′ (SEQ ID NO:48), which binds to genome positions 12492-12528. The downstream flank reverse primer was 5′-GCAAGCCTTATAACGAAGCAAATC (SEQ ID NO:49), which binds to genome positions 14131-14154. A 3-way ligation was performed, using the XhoI-AflII fragment of the 5′ flanking PCR product, the AflII-BsrG1 fragment of the 3′ flanking PCR product, and the large XhoI-BsrGI fragment from plasmid p2_(—)7D-4. All fragments were gel purified following restriction enzyme digestion. The resulting plasmid p2_(—)7D4delta2 was deleted in the region of ORF2 that does not overlap ORF3 or it's 5′ transcriptional regulatory sequences. Two restriction sites that are absent in both the viral genome and the plasmid backbone, AflII and MluI, have been introduced to facilitate directional cloning of foreign genes into the space previously occupied by ORF2.

The changes made in p2_(—)7D4delta2 were incorporated into a full-length genomic clone by replacing the AfeI-BsrGI fragment from pCMV-S-P129 with the modified sequence from p2_(—)7D4delta2. The resulting plasmid pCMV-S-P129delta2 was used for transfections.

Since the deletion of ORF2 is lethal to virus replication, it is necessary to provide this protein in trans to allow generation of ORF2-deficient PRRS virus. This can be accomplished by using a complementing cell line. We created ORF2-expressing MARC-145 cell lines were created by stably transfecting cells with a plasmid containing both the ORF2 gene from P129A and the neomycin resistance gene. After selecting for neomycin resistance using the antibiotic G418, single-cell colonies were expanded and characterized. After transfecting with pCMV-S-P129delta2, three cell clones yielded live viruses that can be propagated and passed only in these ORF2-expressing cells. This virus was designated P129delta2.

Recombinant virus P129delta2 was used to vaccinate groups of 20 sero-negative conventional pigs. At three weeks of age (Day 0) and six weeks of age (Day 20), pigs were vaccinated according to Table 6, below. Controls were mock vaccinated with phosphate buffered saline (PBS). Amphigen adjuvant was not viricidal to the live vaccine virus.

TABLE 6 Various groups of 20 sero-negative conventional pigs vaccinated with P129delta2. Treatment Group Route* Adjuvant Titer/Dose (log10 TCID₅₀) P129delta2 IM IM/IM 5% Amphigen 5.8 P129delta2 IT IT/IT None 5.7 Mock vaccinated IT/IT None NA (PBS) Controls *IM—intramuscular; IT—intratracheal.

At three weeks following second vaccination (Day 42, 9 weeks of age), pigs were challenged with approximately 2.8 mL of virulent P129 challenge virus (3.41×10⁵ TCID₅₀/mL) in each nostril, to achieve a total challenge volume of 5.6 mL (1.91×10& TCID₅₀). Pigs were bled periodically for determination of anti-PRRSV antibody (IDEXX HerdChek PRRS ELISA) and serum viremia (TCID₅₀ assay).

TABLE 7 Anti-PRRSV antibody levels (S/P ratios) Day Day Day Day Day Day Day Day 2 19 28 34 42 52 55 63 P129delta2 IM 0.026 0.132 1.265 1.319 1.389 1.995 2.322 2.02 P129delta2 IT 0.011 0.004 0.026 0.115 0.036 1.306 1.584 1.501 Mock vaccinated (PBS) Controls 0.001 0.002 0.071 0.003 0.004 0.763 1.362 1.395

Two vaccinations with live Amphigen-adjuvanted P129delta2 intramuscularly resulted in a marked increase in anti-PRRSV antibody in the serum prior to challenge, as well as an anamnestic response following challenge. Two intratracheal vaccinations with unadjuvanted P129delta2 were less effective, but nevertheless resulted in a slight increase in antibody level prior to challenge and a more rapid response following challenge, relative to the mock-vaccinated control group.

TABLE 8 Results from two vaccinations with live Amphigen-adjuvanted P129delta2 and control. Serum titer (log 10 TCID₅₀) and number of positive pigs following PRRSV challenge Days post-challenge Treatment 0 5 8 10 14 21 P129delta2 Titer 0.0 1.5 0.3 0.0 0.0 0.0 IM Positive/ 0/19 13/18  4/18  1/18 0/8 0/8 Total (%) (0%)  (72%)  (22%)  (6%)  (0%)  (0%) P129delta2 Titer 0.0 2.3 2.1 1.5 0.5 0.2 IT Positive/ 0/20 19/20 19/20 17/20 4/10 1/10 Total (%) (0%)  (95%)  (95%) (85%) (40%) (10%) Mock Titer 0.0 2.4 2.0 1.4 0.3 0.0 vaccinated (PBS) Controls Positive/ 0/20 19/19 19/19 16/19 3/9 0/9 Total (%) (0%) (100%) (100%) (84%) (33%)  (0%)

Intramuscular vaccination with two doses of live Amphigen-adjuvanted P129delta2 virus resulted in a reduction of the number of viremic pigs (from 100% to 72%), reduction in the duration of viremia (from about 21 days to about 14 days), and reduction in the average serum virus load of nearly one log at 5 days post-infection (the peak of viremia) and more than one log at later times. Intratracheal vaccination with unadjuvanted P129delta2 showed little or no reduction in viremia relative to the mock-vaccinated control group.

Example IX Insertion of Unique MluI and SgrAI Restriction Sites into the PRRS Virus Genome within Nsp2

The QuikChange® II XL Site-Directed Mutagenesis kit (Stratagene; La Jolla, Calif.) was used to introduce a unique MluI restriction enzyme site into the PRRS virus genome at nucleotide position 3,219 using plasmid pCMV-S-P129 as template. Genome position 3,219 lies within the nonstructural protein 2 (nsp2) coding region, which is part of ORF1a (FIG. 5). This site is located within the hypervariable C-terminal portion of nsp2. The sequence of the parental virus beginning at genome position 3,219 (ACACGC) is such that changing only two nucleotides (ACGCGT) allows the introduction of an MluI site without altering the encoded amino acid sequence. The mutagenic primers used to insert the MluI site (MluI F and MluI R) are shown in Table 1. QuikChange II XL reactions were as recommended by the manufacturer and contained 150 picomoles of each primer and 10 ng of plasmid DNA as template. Reaction conditions were as follows: initial denaturation at 95° C. for 60 seconds, 18 cycles of 95° C. denaturation for 50 seconds, 60° C. annealing for 50 seconds, and 68° C. extension for 20 minutes, concluding with a 7 minute incubation at 68° C. Successful introduction of the new site was determined based on the ability of the resulting plasmid to be cut with MluI and confirmed by DNA sequencing. The new plasmid was named pCMV-S-P129-Nsp2-MluI, and was used as a backbone for the insertion foreign DNA fragments.

A unique SgrAI restriction enzyme site was inserted into plasmid pCMV-S-P129-Nsp2-Mlu as follows. A 4500 bp PCR product (genome positions 3201-7700) was amplified using template pCMV-S-P129-Nsp2-Mlu, primers Mlu-F and 7700-R (Table 1), and ExTaq™ polymerase (TakaRa Mirus Bio; Madison, Wis.) according to the manufacturers directions. The forward primer Mlu-F contains the unique MIul site added in the previous step, and the reverse primer 7700-R contains a unique PmeI site to be used in a subsequent cloning step. Reactions conditions were: initial denaturation at 95° C. for 120 seconds, 30 cycles of 94° C. denaturation for 35 seconds, 58° C. annealing for 35 seconds, and 72° C. extension for 4.5 minutes. The resulting PCR product was cloned the TOPO PCR XL cloning kit (Invitrogen Corp.; Carlsbad, Calif.). The QuikChange II XL Site-Directed Mutagenesis Kit was used to introduce a unique SgrAI site beginning at genome position 3614 according to the manufacturers directions. The original sequence TACCGGTG was changed to CACCGGTG without altering the encoded amino acid sequence, using primers SgrAI-F and SgrAI-R (Table 1). Reactions conditions were: initial denaturation at 95° C. for 60 seconds, 18 cycles of 95° C. denaturation for 50 seconds, 60° C. annealing for 50 seconds, and 68° C. extension for 9 minutes, followed by a 68° C. polishing reaction for 7 minutes. After transformation, plasmids containing the new SgrAI site were selected by restriction digestion and sequence analysis. The 4,456 bp MluI-PmeI fragment from this plasmid was ligated to the 14,436 bp MluI-PmeI fragment of PCMV-S-P129-Nsp2-Mlu to yield pCMV-S-P129-Nsp2-Mlu/SgrA. This plasmid was transfected into MARC-145 cells using Lipofectamine 2000 (Invitrogen Corp.; Carlsbad, Calif.) according to the manufacturer's instructions. Three days post-transfection lysates were titrated by limiting dilution. Infectious virus was recovered from plasmid pCMV-S-P129-Nsp2-Mlu/SgrA at levels that were similar to plasmids pCMV-S-P129 and pCMV-S-P129-Nsp2-MIu.

Example X Insertion of Green Fluorescent Protein (GFP) into Nsp2

MluI sites were placed on the 5′ and 3′ ends of GFP, amplified by PCR from plasmid pEGFP-C3 (Clontech, Mountain View, Calif.), using gene-specific PCR primers GFP-Mlu-F and GFP-Mlu-R (Table 1). ExTaq™ polymerase (TakaRa Mirus Bio; Madison, Wis.) was used according to the manufacturer's recommendation. Reactions conditions were: initial denaturation at 95° C. for 120 seconds, 30 cycles of 94° C. denaturation for 35 seconds, 56° C. annealing for 35 seconds, and 72° C. extension for 60 seconds. The PCR product was digested with MluI and ligated into MIul-digested pCMV-S-P129-Nsp2-Mlu. DNA sequencing confirmed that GFP had been inserted in-frame, in the forward orientation, into nsp2. The new plasmid was designated pCMV-S-P129-Nsp2-Mlu-GFP.

Plasmids pCMV-S-P129, pCMV-S-P129-Nsp2-Mlu, and pCMV-S-P129-Nsp2-Mlu-GFP were transfected into the MARC-145 monkey kidney cell line in order to generate infectious virus. Cell lines were maintained at 37° C., 5% CO₂ in modified Eagle's medium (MEM) supplemented with 8% fetal bovine serum, 0.008% Fungizone and 0.01% penicillin/streptomycin. Approximately one day prior to transfection, 2×10⁵ cells/well were seeded into a 12-well plate. Transfection of infectious cDNA clones was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, Calif.) according to the manufacturer's instructions. At 4 days post-transfection, virus was harvested by subjecting the infected cells to three freeze-thaw cycles. Cell debris was removed by centrifugation at 1000×g for 10 minutes, and virus-containing culture supernatants collected. Recombinant viruses rescued from plasmids pCMV-S-P129, pCMV-S-P129-Nsp2-Mlu, and pCMV-S-P129-Nsp2-Mlu-GFP were designated P129, P129-Nsp2-Mlu, and P129-Nsp2-Mlu-GFP, respectively.

To determine virus titer, end-point dilutions were performed on MARC-145 cells in 96 well plates. Titrations were performed in triplicate and results presented as TCID₅₀/ml. Cells were fixed at 3 days post-transfection and immunostained either directly with the nucleocapsid-specific monoclonal antibody SDOW-17 conjugated to FITC, or indirectly with the nucleocapsid-specific primary monoclonal antibodies SR30 or JP24 followed by Alexaflour 594-conjugated goat anti-mouse IgG secondary antibody (Molecular Probes/Invitrogen Corp.; Carlsbad, Calif.). Titers of P129 and P129-Nsp2-Mlu were similar, while the titer of P129-Nsp2-Mlu-GFP was slightly lower. The P129-Nsp2-Mlu-GFP virus expressed GFP and formed fluorescent green foci. Within the focus of infection, cells with perinuclear green fluorescence are seen, due to expression of the Nsp2-GFP fusion peptide.

For western blot analysis, cells were lysed with 100 ul of 2× Laemmli sample buffer and boiled for 10 min. Proteins were fractionated on SDS-polyacrylamide gels (Bio-Rad; Hercules, Calif.) under reducing conditions. Proteins were transferred onto nitrocellulose membranes and processed at room temperature. Membranes were blocked for 1 hr with 5% nonfat dry milk in washing solution (0.2% Tween 20 in PBS). Affinity purified goat anti-GFP antibody (Rockland Immunochemicals Inc., Gilbertsville, Pa.) was diluted 1:1000 in blocking buffer and incubated with membranes for 1 hr. Membranes were washed three times for 15 minutes with TBS-Tween. Rabbit anti-goat horseradish peroxidase-conjugated antibody (Rockland) was diluted 1:1000 in blocking buffer and incubated with membranes for 1 hr. Membranes were washed three times for 15 minutes with TBS-Tween. Peroxidase activity was detected using the Supersignal West Pico Chemiluminescent substrate (Pierce Chemical Company; Rockford, Ill.). Western blots identified a 70 kDa peptide from P129-Nsp2-Mlu-GFP infected cells that reacted with anti-GFP antibody. Using a similar procedure, the GFP gene was also inserted into nsp2 at the SgrAI site in the plasmid pCMV-S-P129-Nsp2-Mlu/SgrA. Primers GFP-SgrA-F and GFP-SgrA-R (Table 1) were used to add SgrAI sites to the ends of the GFP gene, using plasmid pEGFP-C3 as template. ExTaq™ polymerase (TakaRa Mirus Bin; Madison, Wis.) was used according to the manufacturer's recommendation. Reactions conditions were: initial denaturation at 95° C. for 120 seconds, 30 cycles of 94° C. denaturation for 35 seconds, 55° C. annealing for 35 seconds, and 72° C. extension for 35 seconds. The PCR product was digested with SgrAI and ligated into SgrAI-digested pCMV-S-P129-Nsp2-Mlu/SgrA. DNA sequencing confirmed that GFP had been inserted in-frame, in the forward orientation, into nsp2. The new plasmid was designated pCMV-S-P29-Nsp2-SgrA-GFP. This plasmid produced infectious virus and fluorescent green foci when transfected into MARC-145 cells.

TABLE 9 PCR primers used to introduce the heterologous genes. Primer SEQ (genome ID position) Sequence Orientation NO MluI-F CTGTCAAGTGTTAGGATCACG Forward 50 (3201-3242) CGTCCAAAATACTCAGCTCAA MluI-R  TTGAGCTGAGTATTTTGGACG Reverse 51 (3201-3242) CGTGATCCTAACACTTGACAG GFP-Mlu-F GCCACGCGTGCCACCATGGTG Forward 52 AGCAAGGGCGAG GFP-Mlu-R GCCACGCGTGTTATCTAGATC Reverse 53 CGGTGGATCC 7700-R  TCAAGCCGCTGGCGGCTAGCA Reverse 54 (7661-7700) GTTTAAACACTGCTCCTTA SgrAI-F  CTCGGGAAAATAGAAAACACC Forward 55 (3597-3637) GGTGAGATGATCAACCAGGG SgrAI-R  CCCTGGTTGATCATCTCACCG Reverse 56 (3597-3637) GTGTTTTCTATTTTCCCGAG GFP-SgrA-F GCCGCCCACCGGTGAGGTGAG Forward 57 CAAGGGCGAGGAGCTGTTC GFP-SgrA-R GCCGCCCACCGGTGTTGTTAT Reverse 58 CTAGATCCGGTGGATC All sequences are 5′ to 3′. Restriction sites are underlined. Nucleotide positions are based on the sequence of PRRSV strain P129.

Example XI Construction of PRRS Viruses Having a Deleted Portion of Nsp2

The previously made plasmid pCMV-S-P129-Mlu/SgrA (see Example IX) was used as the backbone plasmid for construction of recombinant PRRS viruses lacking a 132 amino acid region of nsp2, and with either green fluorescent protein (GFP) or the influenza hemagglutinin (HA) tag inserted into the deleted region.

The enhanced GFP gene from a commercially available plasmid (pEGFP-C3, Clontech) was PCR amplified using primers that add MluI and SgrAI restriction enzyme recognition sites to the 5′ and 3′ ends, respectively. The forward primer was GFP-MLU-F2

SEQ ID NO. 59 (5′-GCCACGCGTGTGAGCAAGGGCGAGGAGCTG-3′) and the reverse primer was GFP-SgrA-R SEQ ID NO. 58 (5′-GCCCACCGGTGTTGTTATCTAGATCCGGTGGATC-3′). PCR reactions used ExTaq polymerase (TakaRa Mirus Bio, Madison, Wis.) according to the manufacturer's instructions. Reaction conditions included an initial 120 second denaturation at 95 C., followed by 30 cycles of denaturation at 94 C. for 35 seconds, annealing at 55 C. for 35 seconds, and extension at 72 C. for 35 seconds. After digestion of the PCR fragment and of pCMV-S-P129-Mlu/SgrA with MluI and SgrAI, the insert was ligated into the vector to yield plasmid pCMV-S-P129-Mlu-GFP-SgrA. Deletion of the 132 amino acid region and insertion of GFP (257 amino acids) was confirmed by DNA sequencing. This plasmid produced viable virus, which in turn produced green fluorescent foci of infection when transfected into MARC-145 cells and observed under a fluorescence microscope. This virus was designated P129-Mlu-GFP-SgrA.

The HA tag is a small peptide epitope (YPYDVPDYA), derived from the influenza virus hemagglutinin gene, that reacts with commercially available monoclonal antibodies. A synthetic adapter was created by heating and slowly annealing two phosphorylated oligonucleotides, designated “HA tag F” (5′-CGCGCGTATACCCATACGACGTCCCAGACTACGCA-3′) SEQ ID NO. 60 and “HA tag R” (5′-CCGGTGCGTAGTCTGGGACGTCGTATGGGTATA-3′) SEQ ID NO. 681. This adapter, with MluI and SgrAI half-sites, was then ligating into pCMV-S-P129-Mlu/SgrA which was previously digested with MluI and SgrAI. The structure of the resulting plasmid, pCMV-S-P129-Mlu-HA-SgrA, was confirmed by DNA sequencing. An in-frame fusion of the HA tag peptide 9-mer replaces the 132 amino acid deletion in nsp2. The plasmid produced viable virus when transfected into MARC-145 cells. This virus was designated P129-Mlu-HA-SgrA.

In a separate experiment, a simple deletion of the same region (without a simultaneous insertion) was engineered into a different infectious cDNA clone, using a different methodology. The plasmid pCMV-S-P129-PK contains a full-length infectious cDNA clone of the P129 isolate of PRRS virus that was isolated from the serum of an infected pig on primary porcine alveolar macrophage cells, and subsequently passaged 16 times on the porcine kidney cell line PK.9. The PK.9 cell line expresses the CD163 PRRS virus receptor, and is fully permissive to PRRSV infection. A precise deletion of 396 nucleotides, which encodes the 132 amino acid region described above, was generated in pCMV-S-P129-PK using the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene; La Jolla, Calif.) and mutagenic primers P129-PK-3199F (5′-CCCTGGAATTTAAGATCACAGGTGAGATGATCAACC-3) SEQ ID NO. 62 and P129-PK-3637R (5′-CCCTGGTTGATCATCTCACCTGTGATCTTAACACTTGACAG-3′) SEQ ID NO. 63. The resulting plasmid pCMV-S-P129-PK-dnsp2 contained a deletion of nsp2 amino acids 628-759 (confirmed by sequencing), and produced viable progeny virus when transfected into PK.9 cells. This virus was designated P129-PK-dnsp2.

Example XII Development of an ELISA for the Detection of Serum Antibodies to a 132-Amino Acid Portion of Nsp2

The 132 amino acid portion of nsp2 that is deleted in viruses P129-Mlu-GFP-SgrA and P129-Mlu-HA-SgrA is designated P129-nsp2 (628-759). This peptide, RPKYSAQAIIDLGGPCSGHLQREKEACLRMREACDAAKLSDPATQEWLSRMWDRVDMLTW RNTSAYQAFRTLDGRFGFLPKMILETPPPYPCGFVMLPHTPAPSVSAESDLTIGSVATEDIPRI LGKIENT) (SEQ ID NO. 64) was expressed as a recombinant peptide in Escherichia coli, using the pHUE system (Catanzariti A M, Soboleva T A, Jans D A, Board P G, Baker R T. 2004. An efficient system for high-level expression and easy purification of authentic recombinant proteins. Protein Sci. 13:1331-1339). In this expression system, the peptide of interest is cloned and expressed as a histidine-tagged/ubiquitin/PRRS peptide fusion (25 kDa apparent molecular weight on SOS-PAGE). After an initial round of purification by nickel ion affinity chromatography, the histidine-tagged/ubiquitin/PRRS peptide is optionally incubated with histidine-tagged/deubiquinating enzyme to cleave histidine-tagged/ubiquitin from the PRRS peptide, in a second round of nickel ion affinity chromatography, the histidine-tagged/ubiquitin and the histidine-tagged/deubiquinating enzyme are retained on the nickel ion affinity column and the free PRRS peptide is eluted.

The ubiquitin-conjugated P129-nsp2 (628-759) peptide from the first nickel affinity chromatography step was coated on ELISA plates (0.1 ug/ml). Plates were blocked with 10% goat serum. Dilutions of sera from infected and non-infected pigs were made in PBS with 10% goat serum, and added to the blocked plates. After incubation and washing, bound porcine antibodies were detected using biotin-labeled goat anti-swine antibody, followed by avidin-peroxidase. Peroxidase activity was detected using a chromagenic substrate.

Serum from an uninfected control pig was serially diluted from 1:10 to 1:20,480 and applied to the ELISA plates for analysis. Optical density (OD) was below 0.4 in all cases. In contrast, serum from a pig that had previously been infected with the heterologous PRRS virus isolate VR2332 about 200 days earlier reacted in a dilution-dependent manner, giving OD values in excess of 1.2 at 1:10 and 1:20 dilutions, and dropping below an OD of 0.4 only after reaching a 1:640 dilution. The VR2332 virus is quite divergent from the P129 isolate, and the 132 amino acid nsp2 (628-759) peptide from VR2332 (RPKYSAQAIIDSGGPCSGHLEVKETCLSVMREACDATKLDDPATQEWLSRMWDRVDMLT WRNTSVYQAICTLDGRLKFLPKMILETPPPYPCEFVMMPHTPAPSVGAESDLTIGSVATEDVP RILEKIENV) (SEQ. ID NO. 65) shares only 85.6% identity with its homolog that was used in the ELISA assay. This suggests that antigenic epitopes are shared, and that an ELISA of this sort is likely to be robust enough to detect infection with most, if not all, type II (“North American” genotype) PRRS viruses. In addition, the ELISA is sensitive enough to show a strong positive reaction with serum from a pig whose antibody levels have been waning for a long period of time (200 days post infection).

Pigs vaccinated with a virus that lacks the nsp2 (628-759) peptide, due to genetic deletion, are not expected to induce antibodies to this region. It is this ability to differentiate vaccinated and naïve (negative) pigs from pigs that have been exposed to field strains of the PRRS virus (positive) that form the basis of the utility of this invention. Pigs that test positive can be removed from the herd or placed in isolation, thus aiding in the management and possible eradication of the PRRS virus.

Alternatively to the peptides disclosed above, peptides representing the corresponding region from other PRRS viruses can be employed in a diagnostic assay. Numerous examples of such peptides are provided for by the sequences disclosed in SEQ ID. NOs 66-15. That is 50 examples of similarly suitable peptides are provided by the polypeptides disclosed in SEQ ID. NOs 66-115 In addition to those examples, fragments of any of the peptides described can be used as a reagent. Fragments can be as short as ten amino acids, capable of forming and being recognized as an epitope by an antibody molecule, or as long as the entire region. For example, the peptide can comprise amino acids 1-10 of the respective 132 amino acid nsp2 peptide. The peptide can comprise amino acids 2-11 of the peptide. The peptide can comprise amino acids 3-12 of the peptide. Peptides are selected in this fashion by progressively “walking” down the amino acid sequence of the nsp2 fragment, all of the way through to amino acid 132, generating 123 possible 10-mer peptides.

In addition to 10-mer peptides, the fragment can be 11 amino acid residues in length. Beginning with a fragment comprising amino acid 1-11, and progressing to the C-terminal residue. 122 different peptides are possible for the corresponding 132 amino acid region in nsp2. Similarly, the fragment can be 12, 13, 14, 15, 16, 17, 18, 19, 20 or more residues in length, up to 131 residues in length, and such peptides are readily identifiable by beginning at residue 1 and “walking” down the amino acid sequence of the corresponding peptide. There are 7626 such fragments in a peptide of 132 amino acid residues (including the full length peptide). Such a strategy can be applied to the corresponding nsp2 sequence from any strain of PRRS virus, making it possible to have a diagnostic kit specific for that and possibly other related strains of PRRS virus.

Example XIII Infection of Pigs with Recombinant Viruses

To establish the level of attenuation achieved by the deletion of the nsp2 (628-759) peptide, and to evaluate the ability of the deletion to serve as a serological marker, young pigs are infected with the undeleted parental virus P129-Mlu/SgrA, P129-Mlu-GFP-SgrA or P129-Mlu-HA-SgrA. Three groups of 10 conventional weaned pigs, 3 weeks of age, are housed separately. A mock-infected group (6 pigs) is included in the study, and naïve pigs (contact controls, 2 per vaccine group) are commingled with infected pigs in order to evaluate the ability of the viruses to spread. After a week of acclimation, at about 4 weeks of age, pigs are infected with the three viruses, or mock infected, by delivering 2 ml of a diluted virus stock (at 1×10⁴ TCID₅₀/ml) intramuscularly and 1 ml intranasally to each nostril (total dose is 4×10⁴ TCID₅₀/ml). Pigs are monitored daily for clinical signs of disease from day −3 to day 10 (general condition, depression, loss of appetite, sneezing, coughing, and respiratory distress), and rectal temperatures are taken on day −1, 3, 7, and 10. On day 10, half of the pigs in each group (selected by prior allotment) are necropsied in order to examine lung lesions and to sample tissues for virus isolation and histopathology. The remaining pigs are necropsied on day 28. All pigs are weighed on arrival, on day −1 or 0, and at necropsy (day 10 or 28).

Blood (10 ml) is collected from all pigs on days −1 or 0, 3, 7, 10, 14, 21, and 28, into serum separator tubes. Sera are frozen at −80 C. until used for the determination of anti-PRRSV antibodies (by IDEXX HerdChek ELISA), neutralizing antibodies (by serum neutralization assay), and virus isolation (titration of virus infectivity by TCID₅₀ assay). In addition, sera will be assayed for antibodies against the nsp2 (628-759) peptide using the ELISA described in Example XII above. Also, the induction of serum antibodies to GFP or to the HA tag can be determined using commercial kits or reagents.

The viruses with nsp2 (628-759) deleted are attenuated (less virulent) relative to the parental virus P129-Mlu/SgrA, as evidenced by a combination of one or more of the following characteristics in infected pigs: (1) reduced clinical signs, (2) reduced fever, (3) increased weight gain, (4) reduced number or severity of lung lesions, (5) increased neutralizing antibody levels, (6) decreased level or duration of viremia in serum, lung, and/or tonsil tissue, or (7) reduced spread to naïve contact control pigs. Attenuated viruses with these characteristics are useful as live vaccines.

All infected pigs test positive for anti-PRRSV antibodies using a commercial ELISA (IDEXX HerdChek), with seroconversion occurring no later than 21 days post-infection. Only those pigs infected with undeleted parental virus P129-Mlu/SgrA are expected to have antibodies specific to the nsp2 (628-759) peptide, as measured using the ELISA described in Example XII. Such a vaccine virus is useful for differentiating infected from vaccinated animals (DIVA), otherwise known as a negatively marked vaccine.

Sera from pigs infected with P129-Mlu-GFP-SgrA or P129-Mlu-HA-SgrA are assayed for antibodies to GFP and the HA tag, respectively, by detecting these antibodies using commercially available reagents and kits. Such positive serological markers or “compliance markers”, when incorporated into a vaccine, are useful for determining which pigs in a herd have been successfully immunized with the vaccine. In addition, the waning of antibodies against the marker can be used as surrogate for the waning of antibodies against the PRRS virus, giving an indication of when to revaccinate.

In a separate pig study, the ability of an nsp2 (628-759)-deleted PRRS virus to function as a vaccine is tested directly. The P129-PK-dnsp2 virus (Example XI) is used to immunize 4 week old pigs by delivering 2 ml of virus at 2×10⁴ TCID₅₀/ml intramuscularly. After 28 days, these pigs are challenged by infection with a virulent PRRS isolate (NADC20). The severity of the disease induced by the NADC20 virus is compared to disease induced in non-vaccinated (naïve) pigs. A useful vaccine will result in at least partial reduction of disease caused by NADC20, including clinical signs, fever, reduced weight gain, lung lesions, persistent viremia, and spread to contact control pigs.

DEPOSIT OF BIOLOGICAL MATERIALS

The following biological material was deposited with the American Type Culture Collection (ATCC) at 10801 University Blvd., Manassas, Va., 20110-2209, USA, on Nov. 19, 1998 and were assigned the following accession numbers:

Plasmid Accession No. pT7P129A 203488 pCMV-S-P129 203489

All patents, patent applications, and publications cited above are incorporated herein by reference in their entirety.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. 

What is claimed is:
 1. An isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that when it infects a porcine animal it is unable to produce PRRS in the animal yet able to elicit an effective immunoprotective response against a PRRS virus in the porcine animal, wherein said DNA sequence is SEQ ID NO:1 or a sequence homologous thereto, except that it lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus.
 2. The isolated polynucleotide molecule of claim 1, wherein said molecule lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus in ORF 1a or ORF 1b within said DNA sequence.
 3. The isolated polynucleotide molecule of claim 1, wherein said molecule lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 4. The isolated polynucleotide molecule of claim 1, wherein said molecule lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 5. The isolated polynucleotide molecule of claim 1, wherein said molecule lacks at least one DNA sequence encoding a detectable antigenic epitope of North American PRRS virus between amino acids from 616 to 752 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 6. The isolated polynucleotide molecule of claim 1, wherein said molecule lacks the DNA sequence encoding amino acids 628 and 759 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 7. A vaccine for protecting a porcine animal from infection by a PRRS virus, wherein said vaccine comprises: a) A genetically modified North American PRRS virus encoded by an infectious RNA molecule encoded by the isolated polynucleotide molecule according to claim 1; b) An infectious RNA molecule encoded by the isolated polynucleotide molecule according to claim 1; c) The isolated polynucleotide molecule according to claim 1 in the form of a plasmid, or d) A viral vector comprising the isolated polynucleotide molecule according to claim 1; and a carrier acceptable for veterinary use.
 8. The isolated polynucleotide molecule of claim 1, wherein said isolated polynucleotide molecule further comprises at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope.
 9. The isolated polynucleotide molecule of claim 8, wherein translation of the encoded infectious RNA molecule results in formation of at least one protein consisting of a fusion between a PRRS virus protein and said heterologous antigenic epitope.
 10. The isolated polynucleotide molecule of claim 8, wherein said nucleotide sequence that encodes a heterologous antigenic epitope is inserted in ORF 1a or ORF 1b within said DNA sequence.
 11. The isolated polynucleotide molecule of claim 8, wherein said nucleotide sequence that encodes a heterologous antigenic epitope is inserted in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 12. The isolated polynucleotide molecule of claim 8, wherein said nucleotide sequence that encodes a heterologous antigenic epitope is inserted in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 13. The isolated polynucleotide molecule of claim 8, wherein said nucleotide sequence that encodes a heterologous antigenic epitope is inserted between amino acids from 628 to 759 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 14. The isolated polynucleotide molecule of claim 8, wherein said nucleotide sequence that encodes a heterologous antigenic epitope is inserted between amino acids from 616 to 752 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence.
 15. A vaccine for protecting a porcine animal from infection by a PRRS virus, wherein said vaccine comprises: a) A genetically modified North American PRRS virus encoded by an infectious RNA molecule encoded by the isolated polynucleotide molecule according to claim 8; b) An infectious RNA molecule encoded by the isolated polynucleotide molecule according to claim 8; c) The isolated polynucleotide molecule according to claim 8 in the form of a plasmid, or d) A viral vector comprising the isolated polynucleotide molecule according to claim 8; and a carrier acceptable for veterinary use.
 16. A diagnostic kit comprising reagents which are useful for differentiating between porcine animals naturally infected with a field strain of a PRRS virus and porcine animals vaccinated with the vaccine of claim
 15. 17. The diagnostic kit of claim 15 having as one of its components a peptide comprising the amino acid sequences selected from SEQ ID NO. 64 to
 115. 18. The diagnostic kit of claim 16, wherein one of its components is a peptide comprising the amino acid sequence of SEQ ID NO. 64, or a peptide fragment thereof 10 amino acid residues in length or longer.
 19. The diagnostic kit of claim 17, wherein said peptide is optionally a fusion protein. 